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Although Radiopharmacy is more than 50 years old, it is still in a stage of rapid development. This 
dissertation focuses on quality issues in radiopharmacies in developing countries. Guidelines for 
radiopharmacy practice in many countries prescribe complex facilities, especially air handling units, and 
extensive quality assurance and documentation requirements. In developing countries, these guidelines 
are currently not always met. In numerous countries in Africa, enforcement of the international 
guidelines would lead to closure of radiopharmacies, and consequently, loss of Nuclear Medicine 
services. The question arises what the consequences of not meeting the requirements of the guidelines 
are, and if practice can be improved without major expenditure. 
This study considered certain aspects of Good Radiopharmacy Practice (GRP) recommendations and 
collected information from both a relatively well-equipped facility at Tygerberg Hospital (TBH) in 
South Africa, and a more basic radiopharmacy facility at Yaoundé General Hospital in Cameroon 
(YGH) to investigate the conditions that will ensure safe and effective products. Factors assessed include 
efficacy and microbial safety of the radiopharmaceuticals, with some comparison to a state-of-the-art 
Good Manufacturing Practice (GMP) compliant radiopharmacy at the University Medical Centre 
Groningen (UMCG) in the Netherlands.  
An adapted version of the Quality Management Audits in Nuclear Medicine (QUANUM) tool, tailored 
for the radiopharmacy context, was used to determine the status of practice in the two African 
radiopharmacies. Once the current situation and product quality in these radiopharmacies was 
determined, basic, low-cost interventions to minimise deficiencies were implemented at YGH and the 
effects of the interventions were assessed. Where the necessary level of safety and efficacy could not be 
met with currently available systems despite interventions, this was reported. 
The efficacy of radiopharmaceuticals depends on their radiochemical purity. As lack of validation of 
analytical methods was one of the shortcomings noted in the YGH audit, experimentally validating a 






As the provision of clean air and maintenance of air handling systems and equipment require a large 
budget, special emphasis was placed in three further chapters of the dissertation on assessment of 
microbial contamination of products, and measures to ensure sterility of products. At YGH, we reached 
better control of microbiological air quality. This was achieved by the implementation of simple 
microbiological air sampling methods, and subsequent introduction of hygienic and procedural 
improvements. Sterility testing of SPECT radiopharmaceuticals showed a low contamination rate at 
both TBH and YGH. Nevertheless, preparing radiopharmaceuticals in a well-maintained laminar air 
flow cabinet is recommended in order to reduce the risk of contamination of products by airborne 
microorganisms. 
The serious consequences that could arise from not meeting GRP requirements, include transmission of 
microbial infection to patients or administering radiochemically impure products. This dissertation 
presents the first work evaluating an affordable approach of the implementation of GRP in sub-Saharan 
Africa. It is highly recommended to all radiopharmacies in the developing world to adapt GRP in their 









Alhoewel Radiofarmasie al meer as 50 jaar bestaan is daar steeds vinnige ontwikkeling op dié gebied. 
Hierdie verhandeling fokus op vraagstukke ten opsigte van gehaltebeheer in radiofarmasie in 
ontwikkelende lande. In baie lande vereis riglyne vir radiofarmasiepraktyk komplekse fasiliteite, veral 
lugversorgingseenhede, en uitgebreide gehaltebeheer en dokumentasie. Hierdie riglyne word tans in 
ontwikkelende lande nie altyd nagekom nie. In talle lande in Afrika sou afdwing van internasionale 
riglyne tot sluiting van radiofarmasiefasiliteite lei, en as gevolg daarvan tot verlies van 
Kerngeneeskunde dienste. Die vraag ontstaan tot watter gevolge dit lei as riglyne se vereistes nie 
nagekom word nie, en of praktyk sonder groot onkostes verbeter kan word. 
Hierdie werk bestudeer ‘n aantal aspekte van aanbevelings t.o.v. Goeie Radiofarmasiepraktyk (Engels: 
Good Radiopharmacy Practice (GRP)) en versamel inligting van beide ‘n relatief goed toegeruste 
fasiliteit by  Tygerberg Hospitaal (TBH) in Suid-Afrika, en ‘n meer basiese fasiliteit by  Yaoundé 
General Hospital (YGH) in Kameroen, om ondersoek in te stel na die omstandighede wat nodig is om 
veilige en effektiewe produkte te verseker. Faktore wat beoordeel word sluit effektiwiteit en 
mikrobiologiese veiligheid van radiofarmaseutika in. Vergelyking word ook getref met ‘n moderne 
radiofarmasie eenheid by die Universiteits Mediese Sentrum Groningen (UMCG), Nederland, wat aan 
vereistes vir Goeie Vervaardigingspraktyk (Engels: Good Manufacturing Practice (GMP)) voldoen.  
Die “Quality Management Audits in Nuclear Medicine” (QUANUM) hulpmiddel is aangepas om 
spesifiek radiofarmasie omstandighede te oudit en vervolgens gebruik om die stand van praktyk in twee 
radiofarmasie eenhede in Afrika te beoordeel. Nadat vasgestel is wat die huidge omstandighede en 
produkgehalte in die eenhede is, is basiese, lae-koste veranderinge by YGH toegepas om tekortkominge 
te verminder.  Die effek van die veranderinge is vervolgens beoordeel. Waar die nodige vlak van 
veiligheid en effektiwiteit na veranderinge steeds nie bereik kon word nie, is dit aan hospitaalbestuur 
gerapporteer. 
Die effektiwiteit van radiofarmaseutika hang van hul radiochemiese suiwerheid af. Aangesien ‘n gebrek 





effektiewe radiochromatografie metode vir gebruik by YGH eksperimenteel gevalideer as eerste stap 
van regstellende aksies.  
Die vereistes om skoon lug te voorsien en die onderhoud van lugvoorsieningsisteme kan baie duur wees. 
Om hierdie rede is daar in drie verdere hoofstukke van die verhandeling baie klem gelê op beoordeling 
van mikrobiologiese kontaminasie van radiofarmaseutika en maatreëls om steriliteit van produkte te 
verseker. By YGH kon die mikrobiologiese gehalte van die lug aansienlik verbeter word deur toepassing 
van eenvoudige mikrobiologiese lugtoetsing, gevolg deur inwerkingstelling van verbeterings t.o.v. 
higiëne en prosedures. Steriliteitstoetsing van radiofarmaseutika vir enkelfotonemissietomografie 
(SPECT) het lae vlakke van mikrobiologiese kontaminasie van radiofarmaseutika by YGH en TBH 
getoon. Ten spyte van dié bevinding word aanbeveel dat radiofarmaseutika in ‘n laminêre vloeikabinet 
wat korrek in stand gehou word, voorberei word om die risiko van mikrobiologiese kontaminasie van 
produkte te vermider.  
Die ernstige gevolge wat uit nie-nakoming van GRP vereistes kan spruit, sluit oordrag van infeksies aan 
pasiënte of toediening van radiochemies onsuiwer produkte in. Hierdie verhandeling is die eerste 
beoordeling van ‘n bekostigbare benadering tot toepassing van GRP in Afrika suid van die Sahara. Dit 
word sterk aanbeveel dat alle radiofarmasie eenhede in die ontwikkelende wêreld GRP in hulle konteks 








I would like to express sincere thanks to several people without whom this thesis would have been 
impossible. 
Prof Sietske Rubow, my supervisor, was always at hand to provide guidance and assistance, no matter 
how heavy her workload. She has provided sterling mentorship and friendship for which I am immensely 
grateful. 
Dr Hendrikus Boersma made more valuable contributions than can be listed here. He kept things light 
and provided sage advice throughout. I keenly appreciate how lucky I was to have him as a co-
supervisor. 
Prof Faustin Dong à Zok made available the radiopharmacy unit at Yaoundé General Hospital and 
provided valuable advice. 
 
Thanks for all the team working at the radiopharmacies of Yaoundé General Hospital, Tygerberg 
Hospital and the University Medical Centre Groningen for the time and effort they have put into 
collecting data. I would like to extend my gratitude to Prof Annare Ellmann and Prof Jan Pruim without 
whom this work could not have been done. 















Table of Contents 
Declaration ............................................................................................................................................. ii 
Summary ............................................................................................................................................... iii 
Opsomming ............................................................................................................................................ v 
Acknowledgements .............................................................................................................................. vii 
Dedication ........................................................................................................................................... viii 
Table of Contents ................................................................................................................................. ix 
List of Abbreviations ........................................................................................................................... xii 
List of Tables ....................................................................................................................................... xiv 
List of Figures ...................................................................................................................................... xv 
Overview of Authors’ Contributions ................................................................................................ xvi 
Chapter 1  
Introduction ........................................................................................................................................... 1 
Background information ............................................................................................................... 1 
Facility, layout and equipment ...................................................................................................... 2 
Quality Assurance ......................................................................................................................... 4 
Research questions ........................................................................................................................ 6 
Purpose of the proposed research .................................................................................................. 7 
Framework and overall design of the study .................................................................................. 8 
Brief overview of the five papers .................................................................................................. 8 
References Chapter 1 .................................................................................................................. 11 
Chapter 2   
Implementation of a Quality Management System:  Self-assessments in a Sub-Saharan 
Radiopharmacy ................................................................................................................................... 13 
Abstract ....................................................................................................................................... 13 
Introduction ................................................................................................................................. 15 





Results ......................................................................................................................................... 19 
Discussion ................................................................................................................................... 22 
Conclusion .................................................................................................................................. 24 
Declarations for publication ........................................................................................................ 26 
References Chapter 2 .................................................................................................................. 27 
Chapter 3   
Validation of a cost-effective alternative for a  radiochromatography method to be used in a 
developing country .............................................................................................................................. 28 
Abstract ....................................................................................................................................... 28 
Introduction ................................................................................................................................. 30 
Materials and methods ................................................................................................................ 33 
Results ......................................................................................................................................... 37 
Discussion ................................................................................................................................... 43 
Conclusion .................................................................................................................................. 47 
Declarations for publication ........................................................................................................ 48 
References Chapter 3 .................................................................................................................. 49 
Chapter 4  
Implementation of air quality monitoring  in a low-income radiopharmacy unit ........................ 53 
Abstract ....................................................................................................................................... 53 
Background ................................................................................................................................. 55 
Methods ....................................................................................................................................... 57 
Results ......................................................................................................................................... 58 
Discussion ................................................................................................................................... 61 
Conclusion .................................................................................................................................. 63 
Declarations for publication ........................................................................................................ 64 





Chapter 5  
A comparative study of passive air sampling in different radiopharmacies .................................. 68 
Abstract ....................................................................................................................................... 68 
Introduction ................................................................................................................................. 70 
Methods ....................................................................................................................................... 72 
Results ......................................................................................................................................... 72 
Discussion ................................................................................................................................... 75 
Conclusion .................................................................................................................................. 77 
Declarations for publication ........................................................................................................ 78 
References Chapter 5 .................................................................................................................. 79 
Chapter 6  
Evaluation of aspects of practice in two African radiopharmacies ................................................ 81 
Abstract ....................................................................................................................................... 81 
Introduction ................................................................................................................................. 82 
Methods ....................................................................................................................................... 84 
Results ......................................................................................................................................... 86 
Discussion ................................................................................................................................... 90 
Conclusion .................................................................................................................................. 93 
Declarations for publication ........................................................................................................ 95 
References Chapter 6 .................................................................................................................. 96 
Chapter 7  
Discussion and Conclusion ................................................................................................................. 99 
Addenda ............................................................................................................................................. 105 
Addendum to Chapters 1 and 2 ................................................................................................. 106 








List of Abbreviations 
Most abbreviations have been defined in the text when used for the first time. A full list of all 
abbreviations used in this thesis appears below. 
ANOVA Analysis of variance 
CAPA  Corrective and preventive action 
CC  Closed cabinet 
CV  Coefficient of variation 
cps  counts per second 
DMSA  Dimercaptosuccinic acid 
FDA  Food and Drug Administration 
FT  Fingertip testing  
GMP  Good manufacturing practice 
GRP  Good Radiopharmacy Practice 
Gram+  Gram positive  
HMDP  Hydroxymethylene diphosphonate 
HPLC  High-Performance Liquid Chromatography 
IAEA  International Atomic Energy Agency 
ICH  International Council for Harmonisation 
ISO  International Organization for Standardization 
ITLC-SG instant thin layer chromatography- silica gel 
keV  kilo electron volt 





LoC  Level of conformance 
LOQ  Limit of quantitation 
MFT  Media fill testing 
MIBI  Methoxyisobutylisonitrile 
PET  Positron Emission Tomography 
QA  Quality Assurance 
QC  Quality Control 
QUANUM Quality Management Audits in Nuclear Medicine 
RCP  Radiochemical Purity 
RP  Radiopharmaceutical 
RSD  Relative Standard Deviation 
SPECT  Single Photon Emission Computed Tomography 
TLC  Thin Layer Chromatography 
TBH  Tygerberg Hospital 
TSA  Tryptic soy agar 
TSB  Tryptic soy broth 
UMCG  University Medical Centre Groningen 
UPLC  Ultra Performance Liquid Chromatography 
USP  United States Pharmacopeia 





List of Tables 
Table 2.1 The status of the Radiopharmacy unit during the study period ............................................. 17 
Table 2.2 Scoring and compliance status before and after intervention ................................................ 20 
Table 2.3 Severity of non-conformance and interventions ................................................................... 21 
Table 3.1 Accuracy of the proposed method for the 3 compounds ....................................................... 37 
Table 3.2 Accuracy of the proposed method for the 3 compounds ....................................................... 38 
Table 3.3A Intermediate precision results: Different Operators ........................................................... 39 
Table 3.3B Intermediate precision results: Effect of Time ................................................................... 40 
Table 3.4 Robustness of the counter ..................................................................................................... 42 
Table 4.1 Settle plate results in all sites during work (W) and at rest (R) ............................................. 59 
Table 4.2 Fisher's exact test of data from plate exposure before versus after corrective action ........... 60 
Table 4.3 Microbial trends in the closed cabinet in 2017 ...................................................................... 60 
Table 5.1 Percentage of total number of settle plates exceeding relevant colony count limits ............. 73 
Table 6.1 Sterility test results at Radiopharmacy I over 18-month period ............................................ 86 
Table 6.2 Sterility test results at Radiopharmacy II over a 4-year period ............................................. 87 
Table 6.3 Radiopharmacy I operators’ media fill and fingertip test results .......................................... 88 
Table 6.4 Radiopharmacy III media fill and fingertip results ............................................................... 89 
Table A.1 Status of SPECT radiopharmacy at the three hospitals ...................................................... 106 
Table A.2 Staffing scoring .................................................................................................................. 110 
Table A.3 Facility scoring ................................................................................................................... 113 
Table A.4 Purchase of materials scoring  ............................................................................................ 117 
Table A.5 Dispensing protocols scoring ............................................................................................. 119 
Table A.6 Preparation protocols scoring ............................................................................................. 121 
Table A.7 QA/QC scoring ................................................................................................................... 123 
Table A.8 Waste scoring ..................................................................................................................... 129 
Table A.9 Fisher's exact test of data from plate exposure at Radiopharmacy I versus  
Radiopharmacy II ........................................................................................................... 131 
Table A.10 Fisher's exact test of data from plate exposure rest versus work at  





List of Figures 
Figure 2.1 Radar plots showing improvement after implementation of some aspects of GRP ............. 19 
Figure 3.1 Illustration of the robustness test methodology ................................................................... 36 
Figure 3.2 Response of the counter for Tc-99m activity ....................................................................... 41 
Figure 3.3 Linearity of the proposed method for the 3 products ........................................................... 41 
Figure 5.1 Passive air sampling at the 3 radiopharmacies ..................................................................... 74 
Figure 6.1 Simulation of radiopharmaceutical preparation  .................................................................. 85 








Overview of Authors’ Contributions 
Chapter 2: Implementation of a Quality Management System: Self-assessments in a Sub-Saharan 
Radiopharmacy (p13-27) 
 
Declaration by candidate 
With regards to the article presented in chapter 2, the nature and scope of my contribution were as 
follows: 
Nature of contribution Extent of contribution (%) 
Literature review, study design, data collection, processing and 
analysis, manuscript review 
70 
 
The following co-authors have contributed to the article presented in chapter 2 as detailed below: 
 e-mail address Nature of contribution Extent of 
contribution (%) 
Sietske M Rubow smr@sun.ac.za Manuscript review 15 
Hendrikus H Boersma h.h.boersma@umcg.nl Manuscript review 10 
Faustin Dong à Zok dongazok@yahoo.fr Manuscript review 5 
(Declaration with signature in possession of candidate and supervisor.) 
 
Fany Pricile Ekoume 
Date: January 2020 
 
Declaration by co-authors 
The undersigned hereby confirm that 
1. The declaration above accurately reflects the nature and extent of the contributions of the 
candidate and the co-authors in the specified chapters/articles. 
2. No other authors contributed to the specified chapters/articles beside those specified above, 
and 
3. Potential conflicts of interest have been revealed to all interested parties and that the necessary 
arrangements have been made to use the material in the specified chapters/ articles of this 
dissertation. 
Signature Institutional affiliation Date 
Prof Faustin Dong à Zok University of Yaoundé I  
Faculty on Medicine and Biomedical Sciences 
Department of Biophysics, Medical Imaging and 
radiotherapy 
January 2020 
Dr Hendrikus H Boersma University Medical Centre Groningen. 
Department of Nuclear Medicine and Molecular 
Imaging/ Department of Clinical Pharmacy and 
Pharmacology 
January 2020 
Prof Sietske M Rubow Stellenbosch University 
Faculty of Medicine and Health Sciences, 









Chapter 3: Validation of a cost-effective alternative for a radiochromatography method for use in a 
developing country (p28-52) 
 
Declaration by candidate 
With regards to the article presented in Chapter 3, the nature and scope of my contribution were as 
follows: 
Nature of contribution Extent of contribution (%) 
Literature review, study design, data collection, processing and 
analysis, manuscript review 
70 
 
The following co-authors have contributed to the article presented in chapter 3 as detailed below: 
Hendrikus H Boersma h.h.boersma@umcg.nl Manuscript review, study 
design 
15 
Sietske M Rubow smr@sun.ac.za Manuscript review, study 
design 
10 
Faustin Dong à Zok dongazok@yahoo.fr Manuscript review 5 
(Declaration with signature in possession of candidate and supervisor.) 
 
Fany Pricile Ekoume 
Date: January 2020 
 
Declaration by co-authors 
The undersigned hereby confirm that 
1. The declaration above accurately reflects the nature and extent of the contributions of the 
candidate and the co-authors in the specified chapters/articles.  
2. No other authors contributed to the specified chapters/articles beside those specified above, 
and 
3. Potential conflicts of interest have been revealed to all interested parties and that the necessary 
arrangements have been made to use the material in the specified chapters/ articles of this 
dissertation. 
Signature Institutional affiliation Date 
Prof Faustin Dong à Zok University of Yaoundé I  
Faculty on Medicine and Biomedical Sciences 
Department of Biophysics, Medical Imaging and 
radiotherapy 
January 2020 
Dr Hendrikus H Boersma University Medical Centre Groningen. 
Department of Nuclear Medicine and Molecular 
Imaging/ Department of Clinical Pharmacy and 
Pharmacology 
January 2020 
Prof Sietske M Rubow Stellenbosch University 
Faculty of Medicine and Health Sciences, 








Chapter 4: Implementation of air quality monitoring in a low-income radiopharmacy unit (p53-67) 
 
Declaration by candidate 
With regards to the article presented in chapter 4, the nature and scope of my contribution were as 
follows: 
Nature of contribution Extent of contribution (%) 




The following co-authors have contributed to the article presented in chapter 4 as detailed below: 
Hendrikus H Boersma h.h.boersma@umcg.nl Manuscript review, study 
design, data collection 
15 
Sietske M Rubow smr@sun.ac.za Manuscript review, study 
design, data collection 
10 
(Declaration with signature in possession of candidate and supervisor.) 
 
Fany Pricile Ekoume 
Date: January 2020 
 
Declaration by co-authors 
The undersigned hereby confirm that 
1. The declaration above accurately reflects the nature and extent of the contributions of the 
candidate and the co-authors in the specified chapters/articles.  
2. No other authors contributed to the specified chapters/articles beside those specified above, 
and 
3. Potential conflicts of interest have been revealed to all interested parties and that the necessary 
arrangements have been made to use the material in the specified chapters/ articles of this 
dissertation. 
Signature Institutional affiliation Date 
Dr Hendrikus H Boersma University Medical Centre Groningen. 
Department of Nuclear Medicine and Molecular 
Imaging/ Department of Clinical Pharmacy and 
Pharmacology 
January 2020 
Prof Sietske M Rubow Stellenbosch University 
Faculty of Medicine and Health Sciences, 








Chapter 5: A comparative study of passive air sampling in different radiopharmacies (p68-80) 
 
Declaration by candidate 
With regards to the article presented in chapter 5, the nature and scope of my contribution were as 
follows: 
Nature of contribution Extent of contribution (%) 
Literature review, data collection, processing and analysis, manuscript 75 
 
The following co-authors have contributed to the article presented in chapter 5 as detailed below: 
 
Hendrikus H Boersma h.h.boersma@umcg.nl Manuscript review, study 
design, data collection 
15 
Sietske M Rubow smr@sun.ac.za Manuscript review, study 
design, data collection 
10 
(Declaration with signature in possession of candidate and supervisor.) 
 
Fany Pricile Ekoume 
Date: January 2020 
 
Declaration by co-authors 
The undersigned hereby confirm that 
1. The declaration above accurately reflects the nature and extent of the contributions of the 
candidate and the co-authors in the specified chapters/articles.  
2. No other authors contributed to the specified chapters/articles beside those specified above, 
and 
3. Potential conflicts of interest have been revealed to all interested parties and that the necessary 
arrangements have been made to use the material in the specified chapters/ articles of this 
dissertation. 
Signature Institutional affiliation Date 
Dr Hendrikus H Boersma University Medical Centre Groningen. 
Department of Nuclear Medicine and Molecular 
Imaging/ Department of Clinical Pharmacy and 
Pharmacology 
January 2020 
Prof Sietske M Rubow Stellenbosch University 
Faculty of Medicine and Health Sciences, 








Chapter 6: Evaluation of aspects of practice in two African radiopharmacies (p81-99) 
 
Declaration by candidate 
With regards to the article presented in chapter 5, the nature and scope of my contribution were as 
follows: 
Nature of contribution Extent of contribution (%) 




The following co-authors have contributed to the article presented in chapter 5 as detailed below: 
Sietske M Rubow smr@sun.ac.za Manuscript review, study 
design, data collection 
15 
Hendrikus H Boersma h.h.boersma@umcg.nl Manuscript review, study 
design data collection 
15 
(Declaration with signature in possession of candidate and supervisor.) 
 
Fany Pricile Ekoume 
Date: January 2020 
 
Declaration by co-authors 
The undersigned hereby confirm that 
1. The declaration above accurately reflects the nature and extent of the contributions of the 
candidate and the co-authors in the specified chapters/articles.  
2. No other authors contributed to the specified chapters/articles beside those specified above, 
and 
3. Potential conflicts of interest have been revealed to all interested parties and that the necessary 
arrangements have been made to use the material in the specified chapters/ articles of this 
dissertation. 
Signature Institutional affiliation Date 
Dr Hendrikus H Boersma University Medical Centre Groningen. 
Department of Nuclear Medicine and Molecular 
Imaging/ Department of Clinical Pharmacy and 
Pharmacology 
January 2020 
Prof Sietske M Rubow Stellenbosch University 
Faculty of Medicine and Health Sciences, 














With the current expansion of Nuclear Medicine practice in the world, including African countries (Dondi 
et al. 2011), it is important to find out how and if high quality safe radiopharmaceuticals can be prepared in 
low income radiopharmacy units where the environment and the equipment do not meet requirements of 
Good Radiopharmacy Practice (GRP) guidelines. On the one hand, developing countries need Nuclear 
Medicine services, and should not be deprived of them because their radiopharmacies cannot meet very high 
standards. On the other hand, the people of developing countries should not be exposed to unsafe 
radiopharmaceuticals due to deficient radiopharmacy practice.  
Clinical use of radiopharmaceuticals is associated with risk deriving from radiation exposure and possible 
contamination during handling by chemical, biological and microbiological impurities (IAEA 2008, 
European Commission 2008). Another aspect that could affect use of radiopharmaceuticals is the possibility 
of procedural errors. Therefore, their preparation and use are regulated by a number of directives, regulations 
and rules that cover all aspects of radiopharmacy and that must be followed to ensure and prove the quality 
of products (Guilloteau et al. 2007, Hesslewood 1990). Technetium-99m (Tc-99m) radiopharmaceuticals 
are prepared from licenced sterile generator eluates and kits and are classified under operational level 2 in 
the IAEA’s Operational Guidance on Hospital Radiopharmacy. Several PET radiopharmaceuticals are 
produced on-site with complex synthesis reactions and multi-step procedures. The risk of contamination 
during handling such products is higher. For PET radiopharmaceuticals, recommendations for facilities and 
procedures are therefore more rigorous, and they are classified under the operational level 3 (IAEA 2008).  





(GMP) and Good Radiopharmacy Practice (GRP) guidelines, is to ensure the safety and efficacy of the 
product. Guidelines are frequently adapted or rephrased into rules to fit a radiopharmacy’s specific setting.  
Among the main aspects that must be considered when planning a new unit or evaluating an established 
radiopharmacy, are the facility to accommodate the unit, the layout and the equipment. Self-inspection of 
the radiopharmacy unit can reflect the standard at which it operates and help to evaluate the conformance 
to required specifications (IAEA 2008). 
 
Facility, layout and equipment 
The best location for a hospital radiopharmacy unit is within or near the Nuclear Medicine Department first 
of all for containment/ radiation safety reasons, and secondly because of the close relationship between the 
two units. The design mostly depends on the size and type of work in the unit, with a basic prerequisite of 
a clean and safe environment regarding dust, microorganisms and radioactivity (Owunwanne et al. 1995, 
Saha 2010). The unit should be organized in such a way that the risk of cross contamination (i.e. 
contamination of one product with another) is minimised (Callahan et al. 2007).  
Facility layout should not only encompass the primary requirements of GRP and radiation protection 
associated with product handling, but should also enhance the flow of materials and people, and integrate 
the structural elements necessary to achieve these objectives. In this respect, application of controlled access 
in certain areas, interlocks, segregation, and pass-through boxes should be integrated in a building’s design, 
along with the type of structural materials appropriate to meet a facility’s objectives (IAEA 2012). For 
example, ideally, the lay-out should enable unidirectional circulation of people, raw material and final 
product. All items should enter or leave the cleanest areas through transfer hatches, rather than carrying 
them from one area to other. In a radiopharmacy located in a Nuclear Medicine unit, it would be optimal to 
have the dispensing area adjacent or close to the injection area.  
The radiopharmacy should be divided to provide a separate administrative area equipped adequately with 





radiopharmacy should be through a gowning area. In addition to this, a separate reception area should 
provide sufficient space for receipt of products. Where applicable, it is recommended that before release for 
use, incoming products should be segregated and placed in a designated area under quarantine to be 
inspected, sampled and tested before definitive approval and storage for use (Elsinga et al. 2010). 
Radiolabelling of blood cells must preferably be performed in a well separated clean area different to the 
kit dispensing area (Hesslewood 1990). Separate shielded areas for generators and waste should be available 
(Saha 2010). The finishing and layout must provide floors and walls that are easy to clean and 
decontaminate. There should be separation between low and high activity areas. If needed, there could also 
be separation between areas for long and short living radionuclides, including separation of radioactive 
waste containers. Furthermore, the rooms should have sufficient light, and adequate temperature and 
humidity control.  
As microbiological contamination can arise from particles in circulation and personnel movements, 
including talking, sneezing, and coughing, particle-free air supply is deemed essential to ensure sterile 
preparations. The underlying philosophy of the requirement to control the particulate contamination for 
parenterally administered radiopharmaceuticals is that reducing the particle count level lowers the chance 
of microbial contamination in the final product (Hesslewood 1990). A clean air environment plays an 
important role in reducing particulate contamination. For this reason, almost all the guidelines and directives 
available stipulate that preparation of kits and elution of Tc-99m generators should be done in a laminar air 
flow cabinet (LAFC). Appropriate procedures for the disinfection of materials and equipment being 
transferred into the aseptic work area should be available (Elsinga et al. 2010). Consideration must be also 
given to the environment in which such an LAFC is placed, as the room should be provided with filtered 
air, and controlled temperature and humidity. A prescribed number of air changes should be maintained. It 
is recommended to have pressure differentials between cleaner and less clean areas in order to prevent 





In contrast to the recommendations described above, work stations on an open bench or an LAFC without 
any maintenance program and in uncontrolled surroundings are found in many radiopharmacies in 
developing countries1. The reality in many radiopharmacies is that they have been built as laboratories 
without any consideration of the adequate design required for GRP. 
 
Quality Assurance 
Quality assurance is a structured, document-based system aiming to demonstrate compliance to accepted 
and prescribed standards. In a Radiopharmacy, it comprises the total process of preparation of a 
radiopharmaceutical for patients, involving correct radiolabelling, quality control, i.e. testing of equipment 
and radiopharmaceuticals, dispensing and record keeping (Callahan et al. 2007). All equipment used in the 
radiopharmacy should be qualified before its use, including installation, operational and performance 
qualification. Documents tracing all these steps should be kept (Norenberg et al. 2010). All equipment, 
including dose calibrators, radiation contamination monitors, LAFCs, isolators, etc. should be checked and 
maintained on a regular basis with a maintenance logbook (Busemann Sokole and Britten 2015).  
Product quality control is also mandatory. The quality of radiopharmaceuticals should be verified after 
receipt of a new batch and prior to administration to patients. Radionuclidic purity (for example absence of 
molybdenum-99 in technetium-99m) of the preparation is mandatory for quality images without 
unnecessary irradiation of the patient. Radiochemical purity testing is carried out to ensure that the 
radionuclide is present in the desired chemical form. It is most often performed by thin layer 
chromatography. The presence of chemical impurities in the preparation should also be checked before the 
administration of the product (Sharma 2012, Elsinga et al. 2010). Sterility of radiopharmaceuticals should 
also be verified, preferably using a compendial method; although the test results may only become available 
 
1 A brief questionnaire was sent to radiopharmacy units in several African countries. Out of those that responded,  






after the useful shelf-life of the products. To meet the requirements from different guidelines, the validity 
of all analytical methods should be proven following a pre-established validation protocol (Saha 2010), or 
be derived from a compendial method, which has been proven to be adequate to operate without validation. 
In the latter case, limited testing of the method will be sufficient.  
To provide patients with optimal and safe care, Nuclear Medicine professionals, including personnel 
involved in preparing and dispensing radiopharmaceuticals, should be adequately trained. Each 
radiopharmacy unit should operate under the supervision of a responsible person with specific training in 
radiopharmacy. In many developing countries this recommendation is not met (IAEA 2008, Dondi et al. 
2011). 
Documentation and collection of recorded data are integral and key components of GRP. Therefore, data 
from all processes and procedures having direct influence on the quality of products should be collected as 
evidence and should be available as records. The aim of documentation is to provide and ensure an audit 
trail of each operation that takes place in the radiopharmacy unit (IAEA 2008). A systematic verification of 
the entire unit should be done by self-inspection in order to identify serious out of specification situations. 
Subsequent initialisation of urgent corrective actions and recommendation of actions should lead to 
improvements in the overall functioning of the department (IAEA 2008, Elsinga et al. 2010, Solanki and 
Dondi 2008). 
For many reasons, which will differ according to settings of different radiopharmacies, the 
recommendations summarised above may be only partially met or even not met at all. Obstacles may be 
lack of finances, lack of training, lack of technical and engineering support, or environmental constraints 
like irregular power supply. 
Important factors contributing to adherence to recommendations will be the facility, the equipment available 





Problems with the implementation of recommended techniques in hospital radiopharmacy are not unique to 
low income units. A hospital in France reported frequent occurrences of biocontamination of working areas 
(Maia et al. 2008). More stringent hygiene guidelines have also been implemented in radiopharmacy unit 
of Louis-Mourier Hospital in France after evidence of contamination of the working environment by 
microorganisms (Duez et al. 2009). These two examples illustrate the importance of quality assurance 
programmes where radiopharmaceuticals are prepared.  
One of the main issues remains the practicability of the requirements, including the feasibility of 
recommended guidelines and recommendations in practice. If recommended requirements are not met, it is 
important to know to which extent the deviation affects the quality and efficacy of the product and the safety 
of the patient or the working environment. This study focuses on some essential aspects of the existing 
guidelines. It addresses the status of radiopharmacy practice in Africa and considers the requirements to 
provide safe radiopharmaceuticals for patient administration as well as safe working environments. As most 
hospital radiopharmacies in Africa are limited to work at IAEA Operational Level 2, this work focuses on 




The work addresses the following research questions: 
1)  Which aspects of Good Practice can be improved for radiopharmacies in low-income countries?  
2)  Can the radiochemical quality of radiopharmaceuticals prepared for patients be reliably tested in 
developing countries?  
3)  What is the microbial safety level for the production of SPECT radiopharmaceuticals in the two 





Two African radiopharmacies at TBH and YGH are used as examples in the current dissertation and a GMP-
compliant facility at UMCG is used as reference site. To clarify the real situation in each unit, the properties 
of the three radiopharmacies are described in table A.1 in the Addendum. 
The societal value of the current study is that it evaluates the impact of not being able to conform to GRP 
guidelines in developing countries.  
Purpose of the proposed research 
The objective of this study is to evaluate the implementation of some aspects of Good Radiopharmacy 
Practice guidelines in two radiopharmacies in Africa, and the effect that current practice in these facilities 
has on product quality and safety. 
Certain aspects of existing international guidelines for good radiopharmacy practice are investigated in the 
two radiopharmacy units. Methods used at the University Medical Centre Groningen (UMCG) 
radiopharmacy, which operates under GMP conditions, are used where possible and UMCG is used as an 






Framework and overall design of the study 
This study addresses two main themes within radiopharmacy practice.   
1. Efficacy of products prepared, using radiochemical purity as indicator  
2. The effect of facilities and equipment that fail to provide the recommended level of air cleanliness on 
microbiological aspects of product safety.  
The two themes are each developed as a specific objective which contributes to the main objective of the 
study by its impact or contribution on good radiopharmacy practice. 
Specific objective 1: To evaluate the operational standard and the conformance to required specifications 
at the YGH radiopharmacy 
Specific objective 2: To validate the radioactivity detection method used for radiochemical purity of 
radiopharmaceuticals used at YGH 
Specific objective 3:  To evaluate the air quality in the radiopharmacies at TBH and at YGH 
Specific objective 4: To evaluate the rate of microbial contamination of radiopharmaceuticals at TBH and 
YGH as well as the aseptic skills of operators at YGH 
 
Brief overview of the five papers 
A description with self-audits of the three radiopharmacies included in this study is presented in the 
addendum of the dissertation (tables A.1 to A.8 and figure A.1). 
The research is presented as a series of five articles, of which one has been published in the EJNMMI 






The topics of the five articles are: 
1) Implementation of a Quality Management System: Self-assessments in a Sub-Saharan Radiopharmacy:  
This paper describes a prospective evaluation of the implementation of quality management in a sub-
Saharan radiopharmacy via two self-assessments.  
2) Validation of a cost-effective alternative for a radiochromatography method to be used in a developing 
country:  
A validation of the method used for quantifying the distribution of radioactivity during radiochemical purity 
determination of products is presented. The paper addresses the need for a simple and affordable instrument 
for reading of radiochromatograms.  
The next three articles describe the implementation and evaluation of some aspects of good practice relating 
to microbial safety in two African radiopharmacies.  
3) Implementation of air quality monitoring in a low-income radiopharmacy unit  
Paper 3 presents the prospective implementation of air quality monitoring, using passive air sampling by 
settle plate exposure at YGH radiopharmacy.  After a baseline study, some corrective actions are introduced 
and evaluated during a further monitoring period to evaluate the impact of changes.  
4) A comparative study of passive air sampling in different radiopharmacies 
This paper presents a comparison of air quality monitoring results in the radiopharmacies at YGH and TBH 
and considers approaches to address shortcomings.  
5) Evaluation of aspects of practice in two African radiopharmacies 
The last paper describes the evaluation of aseptic skills of staff at YGH by media fill and fingertip testing. 
It also reviews the sterility test results of radiopharmaceuticals prepared at TBH and YGH and compares 
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Abstract 
Appropriate standards of good practice in Nuclear Medicine and Radiopharmacy are essential, not only in 
developed countries. The Yaoundé General Hospital radiopharmacy unit has started to implement aspects 
of good practice and self-assessments in 2017. This study compares the outcome of audits conducted before 
and after implementation of some aspects of Good Radiopharmacy Practice in order to improve the safety 
and efficacy of radiopharmaceuticals prepared in the radiopharmacy. 
Methods: Based on tools published by the International Atomic Energy Agency, self-assessments of the 
unit were performed to evaluate the level of compliance to good practice, to identify the areas of non-
conformance, and to monitor the effect of changes after the introduction of corrective actions. 
Aspects reviewed for conformity with standards were staffing, facilities, purchase of materials, dispensing 





status of compliance and the level of compliance of each requirement were evaluated and Wilcoxon signed 
rank tests were used with P<0.05 considered significant. 
Results: There were non-conformities in all items in the checklist. Initially, the lowest compliance 
percentage was found with dispensing protocols (20%). Most of the components show significant 
improvement.  
Conclusion: Implementation of the action plan after initial self-assessment, and the outcome of a follow-
up self-audit show improvement of the quality of practice at the Yaoundé General Hospital radiopharmacy. 
Optimized control and documentation and further improvement of the facility are recommended to address 
the remaining risks. 









Organisations implement quality management systems in order to improve the efficiency and effectiveness 
of performance, and to fulfil regulatory requirements. Auditing may be a requirement for accreditation of 
Nuclear Medicine departments (Jarrit 2004; Mirzaei et al. 2011); and is regarded as an essential tool in the 
modern health care system (Begum et al. 2016). An organizational audit process for Nuclear Medicine 
departments was developed by the British Nuclear Medicine Society for both external and internal audits 
(Jarrit 2004). In 2008, the International Atomic Energy Agency (IAEA) published guidelines for hospital 
radiopharmacy practice which included lists of questions for self-audits (IAEA 2008a). The IAEA also 
introduced an auditing system, referred to as Quality Management Audit in Nuclear Medicine (QUANUM), 
aiming to support annual systematic audits in clinical Nuclear Medicine (IAEA 2008b). The second edition 
of the QUANUM manual introduced radar plots and a five-step scoring system which facilitates comparison 
with earlier audits (IAEA 2015). 
Many Nuclear Medicine units and radiopharmacies strive to upgrade their quality management systems, 
aiming at harmonization and standardization to meet internationally recommended Good Practice guidelines 
as far as possible. All areas of an organisation’s activities are generally reviewed with a standardized scheme 
with systemic review questionnaires, defined minimum requirements, and well-defined conformance 
criteria and report formats (Begum et al. 2016). Guidelines for radiopharmacy practice have been published, 
amongst others by the IAEA, to assist with standardization of radiopharmacies (IAEA 2008a, IAEA 2008b). 
In developing countries, it is not always possible to meet all good radiopharmacy practice requirements. 
There is therefore a risk that radiopharmaceuticals prepared or compounded in such sub-optimal facilities 
may not meet the required safety and efficacy standards. Like many other sub-Saharan African 
radiopharmacies, Yaoundé General Hospital (YGH) does not have a suitable facility and all recommended 
equipment for optimal Good Radiopharmacy Practice (GRP) to be achieved. The risk of microbial 
contamination and presence of radiochemical impurities in the products can lead to transmission of 





irradiation. Regular self-audits of the radiopharmacy will promote better control and can help to reduce the 
risks related to radiopharmaceuticals provided by the radiopharmacy.  
YGH radiopharmacy is located within the Nuclear Medicine department with facilities for preparation of 
SPECT radiopharmaceuticals and low dose iodine-131 therapy. The radiopharmacy works at operational 
level 2a as defined in the Operational Guidance on Hospital Radiopharmacy (IAEA 2008a). As illustrated 
in table 2.1, all operators working in the unit have previously received basic training in general 
radiopharmacy during their nuclear medicine training. Following the trend of implementing good standards 
of practice in Nuclear Medicine and Radiopharmacy, the YGH radiopharmacy unit introduced several 
aspects of good practice in 2017. To efficiently focus on relevant aspects, an initial self-assessment was 
conducted. An action plan was organized with a number of activities, including but not limited to, the 
development of awareness of the QUANUM tool among staff, development and upgrading of standard 
operating procedures (SOPs), and improving microbiological and radiation safety in the radiopharmacy. 
This was followed by another self-audit to evaluate the effect of actions.  
The objective of this study is to compare the outcome of self-assessments conducted at YGH before and 
after implementation of aspects of Good Radiopharmacy Practice (GRP), in order to ensure safety and 






Table 2.1 The status of the YGH Radiopharmacy unit during the study period 
Components Status 
Staff and training Responsible person: MSc Radiopharmacy 
1 Nuclear Medicine technician with six months training in a well-
equipped unit  
1 Scientist with a Bachelor’s degree in Biology with 4 months 
training in a well-equipped unit  
1 Scientist with a Bachelor’s degree in Biology and European 
course in radiopharmacy level 1   
1 Chief nurse with 3 months training in a well-established unit in 
Europe 
Equipment 1 glove box (not clean air) 
1 fume hood 
1 laminar air flow cabinet  
1 shielded dispensing area   
1 dose calibrator  
3 radiation contamination monitors  
Radionuclides  99mTc, 131I 
Radiopharmaceuticals  
 
MIBI (methoxyisobutylisonitrile), DTPA (diethylene triamine 
penta acetic acid), HMDP (hydroxy methylene diphosphonate), 







Based on the existing tools from the Operational Guidance on Hospital Radiopharmacy (IAEA 2008a), the 
QUANUM process (IAEA 2008b; IAEA 2015; Dondi et al. 2017; Dondi et al. 2018) and the status of the 
unit during the period of study as presented in table 2.1, self-assessments of the unit were performed to 
evaluate the level of compliance to good practice and to identify areas of non-conformance. The audit 
questions are shown in the Addendum, tables A.2 to A.8. After a first self-assessment (pre-implementation) 
to identify problems, realistically achievable and affordable corrective actions were introduced. These 
included validation of the method to test radiochemical purity (RCP), updating procedures and processes to 
recommended standard operating procedure (SOP) format, implementation of passive air sampling, sterility 
testing and media fill testing, staff training, rearrangement of items in the unit aiming for the reduction of 
contamination in the compounding area, and acquisition of sterile laboratory coats and shoes (easy to clean) 
dedicated to wear only in the radiopharmacy. A second self-assessment was conducted after completion of 
corrective actions to monitor the effect of changes.  
Components relating to the production of radiopharmaceuticals were reviewed for conformity with 
standards described in the IAEA guidance (IAEA 2008a). Aspects reviewed were staffing, facilities, 
purchase of materials, dispensing protocols, preparation protocols, Quality Control/Quality Assurance 
(QC/QA), and waste. Depending on the level of adherence to each recommended standard, the level of 
conformance (LoC) was graded as follows: 0 when the component was absent in the unit; 1 when the 
component was planned; 2 when the component was partially implemented; 3 if the component was largely 
implemented, and 4 when it was fully implemented. Items scoring 0, 1, or 2 are considered non-compliant. 
Those that scored 3 and 4 are conforming. The sum of all grades for individual requirements or criteria 
within a component was expressed as a percentage of the maximum possible score for that component. 
Depending on the impact the non-conformities may have on the environment, on daily practice or on safety, 
the IAEA guidelines (IAEA 2008a; IAEA 2008b) classify them as critical, requiring immediate action, or 





Scores of self-assessments for all components from the checklist before and after intervention were 
compared and visualised using radar plots. The change of status of compliance and the level of compliance 




The scoring and compliance status of the YGH radiopharmacy are summarised in table 2.2. The level of 
conformance (LoC) percentages of each component differed greatly before and after some aspects of Good 
Practice were implemented (figure 2.1). This difference was significant for most components, but the 
number of questions in three components was too low to reliably prove significance of the results. Table 2.3 
summarises the severity of non-conformances and also lists examples of the interventions that led to the 




















Table 2.2 Scoring and compliance status before and after intervention 
Component 







No of Applicable questions 13 12 6 5 5 31 3 75 
Maximum achievable score 52 48 24 20 20 124 12 300 
Total score before intervention 29 9 11 8 11 36 8 112 
LoC before intervention 56% 19% 46% 40% 55% 29% 67% 37% 
Total score after invention 40 24 22 19 17 104 12 238 
LoC after intervention 77% 50% 92% 95% 85% 84% 100% 79% 
Wilcoxon signed rank test*  P<0.001 P<0.001 P<0.001   P<0.001   





Table 2.3 Severity of non-conformance and interventions 
 No of non-conformities  
before / after intervention Examples of interventions 
 Critical  Major  
Staffing 3 / 1 2 / 0 • Staff training 
• Introduced annual performance review to check 
competence 
Facility 4 / 2 5 / 2 • Introduced evaluation LAF cabinets  
• Installed transfer hatch 
• Rearrangement of room lay-out 
Purchase of 
materials 
1 / 0 2 / 0 • Improved record keeping 
Dispensing 
protocols 
2 / 0 1 / 0 • Introduced SOPs 
Preparation 
protocols 
1 / 0 2 / 0 • Improved SOPs and records 
QC/QA 5 / 1 16 / 2 • Improved SOPs and records 
• Validated RCP method 
• Microbiological QC 
• Sterile coat and shoes for radiopharmacy use only 
Waste 
management 








Assuming that a unit working with good practices is more likely to have good outcomes (Mirzaei et al. 
2011), we assumed that upgrading our procedures according to GRP standards could improve our 
radiopharmacy’s performance. De Paula et al. recently did an adaption of the QUANUM tool for 
auditing Brazilian Nuclear Medicine and argued that existing audit tools should be adapted to fit local 
regulations (De Paula et al. 2018). Audit tools should be reviewed to meet changes in Nuclear Medicine 
equipment and practice (Jarrit 2004). Using the QUANUM audit tool to evaluate 25 Nuclear Medicine 
units, improvement in standards of quality in production and use of radiopharmaceuticals could be 
shown in all audited departments (Dondi et al. 2018). However, the QUANUM system (Dondi et al. 
2017) was designed primarily to evaluate Nuclear Medicine centres. As more extended questions on 
quality assurance and quality control were needed to address microbial safety and efficacy of 
radiopharmaceuticals, we adapted the QUANUM model to specifically address the quality of work in 
our radiopharmacy, by focussing in more depth on the different components of radiopharmacy practice, 
using information from the Operational Guidance on Hospital Radiopharmacy (IAEA 2008a). With this 
modified tool, the main areas of weakness could be identified and the positive impact of our corrective 
action plan could be demonstrated. The radar plots adopted from QUANUM were valuable to illustrate 
the original status and improvements for staff members. 
The evaluation in the current work was twofold: firstly, we focused on the change in the total score for 
each component (% values shown in radar plots), and secondly on the change in the level of 
conformance. When both score 3 and score 4 are regarded as conforming, it is clear that a component 
with many requirements that achieved individual grades of 3, and only a few graded 4, will be seen as 
conforming, even though further improvement would be required to completely meet international 
recommendations. 
The radar plot and the table from the initial self-assessment reveal non-conformities in all items audited 
in the checklist. In the first audit, staffing, preparation protocols, and waste management already present 
compliance percentages above 50%. This can be ascribed to the fact that all operators working in the 





educational sessions in radiation protection including radioactive waste management. Staff working 
with unsealed radioactive sources should renew their radiation protection certificates every 2 years.  
The follow up self-assessment shows improvement for all components, with significant differences in 
level of compliance before and after the implementation of corrective actions for aspects related to 
staffing, facilities, purchase of materials and QC/QA. 
The number of non-conformities drops to zero after corrective action for the purchase of materials, the 
dispensing protocols, the preparation protocols and waste management. The problems identified in 
purchase of materials consisted mostly of poor record keeping (e.g. not keeping record of all details). 
This was addressed through staff training on the importance and relevance of recording the information. 
The dispensing and preparation protocols were initially not very well structured. They were re-written 
in SOP format with step-by-step details. As mentioned, staff were already well aware of waste 
management principles at the time of the first audit. In this case introduction of better shielded waste 
containers led to an improved score.   
QC/QA is now much better implemented. If radiopharmacy staff pay close attention to details of QC/QA 
procedures, this improvement may be sustained or even improved. A critical non-conformity that could 
not be immediately addressed is the absence of staff or external technicians who are able to calibrate 
equipment. This is now addressed by a plan for training a medical physicist to work in the unit.  
Additional action is needed to upgrade the facility and equipment. Service and maintenance of 
equipment should be improved, but there are no qualified technicians and spare parts in the country. 
After the second audit the hospital recruited a maintenance engineer who will be trained to address this 
problem. Items were rearranged in the unit to allow smooth and unidirectional transfer of materials from 
the less clean area to cleaner areas. Sterile coats dedicated for wear only in the radiopharmacy and shoes 
reserved for wear in the radiopharmacy were provided. Adequate instructions were introduced to reduce 
staff movement and traffic in the radiopharmacy rooms. A hatch was installed for product transfer from 
the dispensing area to the injection room. The design of the rooms is however not optimal yet. Funds 





Recommendations were made to authorities in this regard. Frequent interruptions of electrical power 
supply also pose a challenge. Due to these problems, two critical and two major non-conformities remain 
for the facility component. 
Despite lack of funding and other practical problems, we achieved satisfying results. The overall LoC 
for the radiopharmacy was 37% before and 79% after implementing changes. Although we have thus 
reached more than the 70% which is regarded as good level of practice in the QUANUM audits of 
Nuclear Medicine departments (Dondi et al. 2017), the nature of risks associated with 
radiopharmaceuticals justifies setting a higher goal. As shown in table 1, the unit is made of 2 rooms 
with QC area included in the preparation room. A shielded laminar air flow cabinet or isolator placed in 
a purpose-designed cleanroom with HEPA filtered air, reserved for compounding or preparation and 
dispensing of radiopharmaceuticals, with a separate room for QC, would be optimal. A softwall or 
modular hardwall cleanroom within a bigger room may possibly be an option.  If the room and air supply 
cannot be altered, strict protocols to minimise the risk of microbiological contamination and stringent 
monitoring are essential.  Regular assessments will also motivate staff to continue implementing good 
practice. 
A limitation of the current study is that the outcomes are based on only two audits. The study was 
designed to first audit the radiopharmacy to evaluate if any improvements in the radiopharmacy were 
needed. A post implementation audit was done after corrective actions but no long term or longitudinal 
evaluations were planned at that time. More follow up audits of the unit are required to ascertain if the 
improvement found in the study can be sustained for a longer period. 
 
Conclusion 
Implementation of an action plan after initial self-assessment, and the outcome of a follow-up self-audit 
in the current study show improvement of the quality of practice at the YGH radiopharmacy, with both 
scores and compliance status revealing positive changes. Further optimized control and documentation 





What is already known on this topic  
- Self-audits are regarded as an essential tool in Quality Management and are expected in GMP-
compliant radiopharmacies in developed countries but is still not performed in many African 
radiopharmacies due to lack of skills. 
- A detailed questionnaire on radiopharmacy practice was published by the IAEA in 2008. 
- The IAEA developed a tool for auditing Nuclear Medicine practice, called QUANUM.  
 
What this study adds 
- This is the first work publishing an evaluation of the implementation of GRP in a sub-Saharan 
radiopharmacy. 
- This study adapted the QUANUM tool to focus on radiopharmacy, using an IAEA 
radiopharmacy questionnaire. This adapted tool can be easily implemented in any 
radiopharmacy in developing countries. 
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Abstract  
Introduction: The radiochemical purity (RCP) of technetium-99m labelled radiopharmaceuticals (RP) 
is important to ensure optimal scintigraphic image quality. In low-income settings, it may not be possible 
to use compendial analytical methods or expensive equipment for radiochemical purity analysis. All 
radiochemical analysis methods should however be validated against compendial or otherwise proven 
methods. To ensure the efficacy of RP prepared at Yaoundé General Hospital (YGH) Cameroon, this 
study cross-validated a cost-effective routine chromatographic method using a simple survey meter 
technique. A GMP-compliant method used at the University Medical Centre Groningen (UMCG), the 
Netherlands was used as the comparator.  
Methods: Sestamibi, HMDP and DMSA kits currently used at YGH were reconstituted at UMCG with 
about 2000 MBq of freshly eluted sodium pertechnetate as described by the manufacturer, and spiked 
with eluate of the same generator to obtain a range of impurity concentrations. Samples of  
technetium-99m RP were spotted on 1x10 cm iTLC-SG strips and developed in appropriate mobile 
 





phases. Each strip was first scanned on the chromatogram-scanner used at the UMCG (standard method), 
and immediately thereafter the strip was cut in two pieces and radioactivity from each portion was 
counted with a small survey meter from YGH. The percentage RCP for each TLC strip was calculated 
using both counting methods. Internationally recommended validation parameters and acceptance 
criteria were used. Student’s paired t-test or ANOVA were used with ‘no significant difference’ 
designated at a 95% confidence-interval (P≥0.05). Linearity of the survey meter was determined for Tc-
99m. Readings obtained with the survey meter were also plotted against the scanner results.   
Results and Discussion: The proposed method proved to be accurate (CV of mean RCP <2), precise 
(RSD <2%), linear (slope close to 1, r2 ≥0.99) within the RCP range of approximately 80% to 100%, 
and robust (P>0.05). LOD and LOQ were determined for the survey meter. Specificity depends on 
chemical separation. As we were validating the suitability of a method to quantify radioactivity, 
specificity was not included in the validation parameters.  
Conclusion: The proposed method compared well with the standard-method and is suitable as a reliable 
low-cost method for limited resource settings.  













1. Importance of method validation 
Nuclear Medicine needs optimal quality radiopharmaceuticals for accurate diagnosis and therapy of 
diseases (IAEA 2008; Dondi 2011). As the use of Nuclear Medicine increases in developing countries, 
including those in sub-Saharan Africa, so does the need for radiopharmaceuticals. With the increasing 
demand for radiopharmaceuticals, it is of paramount importance to ensure that only safe and effective 
products are administered to patients (IAEA 2016). Even though most radiopharmaceuticals in sub-
Saharan Africa are prepared in small scale units, quality assurance programs should be implemented 
(Elsinga et al. 2010). Internationally, guidelines for Good Radiopharmacy Practice recommend that only 
validated analytical methods should be used to evaluate product quality before patient use. Quality 
assurance (QA) in the production of radiopharmaceuticals ensures that they are of sufficient quality for 
their intended purpose; it reduces the possibility of producing substandard products by adhering to 
specified procedures and protocols (Vincenti et al. 2016). Analytical Quality Control (QC) methods 
form part of quality assurance, helping to assess the quality of the product. According to Ajay et al., 
validation of analytical methods provides evidence that the method is suitable for it intended use, and 
thus helps to ensure provision of safe and effective final products (Ajay et al. 2012). The consequence 
of using unvalidated non-compendial methods could result in the administration of unknown substances, 
poor quality images and/or an unnecessary radiation exposure of patients (Amin et al. 2011; Vincenti et 
al. 2016). 
2. The principle of validation of quantitative analytical methods 
Validation of an analytical procedure is the process to ensure that the performance characteristics of the 
procedure adopted in a particular laboratory meet the requirements for the intended analytical 
application (The United States Pharmacopeial Convention<1225> 2008). In radiopharmacy, one of the 
most frequently used analytical criteria is radiochemical purity (RCP) of the product. The radiochemical 
purity of a preparation is the fraction of the total radioactivity in the desired chemical form of the 





of incomplete radiolabelling or decomposition products due to the presence of oxidizing or reducing 
agents, radiolysis or change of temperature and pH (Saha 2010; Millar et al. 2009; Loveless 2009; 
Mambilima 2016). 
RCP can be assessed by various analytical techniques, for example paper, thin layer, or liquid 
chromatography and electrophoresis. Radiochromatography involves the separation of components in 
solution (depending on their affinity with the chromatography materials), and the measurement of the 
distribution of radioactivity on the chromatogram (Saha 2010). 
International guidelines describe validation parameters and acceptance criteria for validation of 
analytical methods, including accuracy, precision, intermediate precision, linearity, range, specificity, 
robustness, detection limit and quantitation limit (The United States Pharmacopeial Convention <1225> 
2008; EDQM 2018).  
3. Validation studies of radiochemical analysis methods in literature 
In the literature, analytical methods’ performance characteristics for both SPECT (Single Photon 
Emission Computed Tomography) and PET (Positron Emission Tomography) radiopharmaceuticals 
differ slightly from one study to another. The parameters recommended by the ICH (International 
Council for Harmonisation, 2006), namely accuracy, precision, linearity and range, specificity, 
robustness and limit of quantitation (LOQ), are frequently used, especially for HPLC (High-
Performance Liquid Chromatography) methods. However, it should be noted that radio-TLC and radio-
HPLC express RCP as a ratio between counts or areas, without requiring absolute quantitative 
measurement of either the product or impurities. In this scenario, accuracy and LOQ, which both address 
quantitative measurement, may not be relevant for radio-HPLC or radio-TLC (Todde et al. 2014), or 
may need a different approach than in the case of chemical analyses. 
Mihon et al. mention the ICH parameters for the HPLC determination of identity and RCP of [18F]NaF 
(Mihon et al. 2016). Leonardi et al. use these parameters in the validation of a paper chromatography 
method as an alternative for determination of the RCP of [18F]NaF (Leonardi et al. 2012). Seetharaman 





[99mTc]Tc-MAG3 by determining specificity, linearity, and robustness. They compare their method 
against a standard method to evaluate accuracy and precision. Acceptance criteria for analytical method 
validation may require adjustments according to the type of equipment: radio-HPLC, radio-UPLC (Ultra 
Performance Liquid Chromatography), radio-TLC (Thin Layer Chromatography), or gamma 
spectrometry (Todde et al. 2017). Besides performance characteristics related to the method of analysis, 
analytical method validation could differ regarding experimental details such as mobile phase, stationary 
phase, flow rate, and wavelength of UV detectors (Todde et al. 2017).  
Several studies describe the development of alternative chromatography procedures to replace ‘gold-
standard’ methods for reasons including simplified technical handling and more rapid processing times. 
Faria et al. in 2015 studied an alternative chromatographic system for the quality control of MIBI where 
they evaluated different solvents to optimize separation efficiency, reproducibility, and analysis time 
(Faria et al. in 2015). This was, however, not a full validation study as defined in documents of normative 
character: ISO (International Organization for Standardization), ICH, FDA (Food and Drug 
Administration) (Krause 2002; The United States Pharmacopeial Convention <1225> 2008), with 
performance characteristics evaluated against acceptance criteria from references. Luebke et al. (2000) 
also evaluated an alternative testing method for the radiochemical purity determination of MIBI but did 
not include all parameters recommended in guidelines (The United States Pharmacopeial Convention 
<1225> 2008). Something similar was done for 99mTc-Annexin A5, using a binding assay instead of 
radio-TLC for determination of radiochemical purity as a release method (Boersma et al. 2004).  
A variety of methods for quantification of distribution of radioactivity on radio-TLC plates are described 
in literature. Decristoforo and Zolle provide an overview of seven methods used for 99mTc 
radiopharmaceuticals, including cutting and counting in a scintillation counter, chromatogram scanning, 
analysis by linear analyzer and phosphor-imager autoradiography (Decristoforo et al. 2007). The 
methods differ regarding sensitivity, resolution and linearity, but differences in time required per 
analysis and the cost of equipment of each of these methods are considerable, making their adoption in 
resource-poor developing countries challenging. At Yaoundé General Hospital in Cameroon (YGH) 





radioactivity or chromatograms of radiopharmaceuticals can be analyzed. An alternative method was 
therefore sought, namely counting sections of the chromatography strips corresponding to the 
distribution of the different radiochemical species with a contamination monitor available in the Nuclear 
Medicine department at YGH. Prior to employing it in daily practice, this proposed method had to be 
validated. The work described herein was performed to validate a cost-effective method for quantifying 
the distribution of radioactivity on chromatography strips using a RadEye B20 contamination monitor 
(available at YGH), and comparing it to the already validated method routinely used at the UMCG in 
the Netherlands.  
 
Materials and methods 
1. Materials for product preparation and chromatography 
All experiments were performed at the UMCG radiopharmacy in the Netherlands. SPECT 
radiopharmaceutical kits Stamicis (2-methoxyisobutylisonitrile: MIBI), Osteocis (hydroxymethylene 
diphosphonate: HMDP), and Renocis (dimercaptosuccinic acid: DMSA), all from Curium, France, 
currently used for nuclear medicine imaging at YGH, were used for this study. Technetium-99m  
(99m Tc) was obtained from an Ultra-Technekow generator (Mallinckrodt Medical BV, Netherlands). 
TLC scanning was performed using a VCS-103 scanner (Comecer S.P.A., Italy) used at UMCG. A 
calibrated RadEye B20 multipurpose counter (Thermo Fisher Scientific Messtechnik, Germany) was 
brought from YGH and used at UMCG for the comparative experiments. Chromatography was done 
using iTLC-SG sheets (Varian) with butan-2-one (methyl ethyl ketone) (Fluka) or 0.9 % saline solution 
(B Braun) as mobile phases.  
2. Sample preparation 
Freshly eluted technetium-99m sodium pertechnetate ([99mTc]NaTcO4) was used to prepare each 
radiopharmaceutical following the kit manufacturer’s instructions or summary of product characteristics 
(Osteocis 3mg 2016; Renocis 2010; Stamicis 2016). Technetium-99m-radiopharmaceutical kits 
([99mTc]Tc-HMDP, [99mTc]Tc-MIBI and [99mTc]Tc-DMSA) each from a single lot were prepared  and 





evaluate. The radiochemical purity aimed for in the spiked products ranged between approximately 80% 
and 100%. 
Each of the cold kits included in this study was reconstituted with approximately 2000 MBq 
[99mTc]NaTcO4] read with the dose calibrator (VDC 404 Veenstra, Joure). 
3. Chromatography of radiopharmaceuticals 
A drop of the same Tc-99m eluate used for kit reconstitution (and to spike the radiopharmaceuticals) 
was used to run a control analysis under the same conditions as those of the radiopharmaceutical 
samples. 
Five µl of [99mTc]Tc-RP samples was spotted on 10 cm  iTLC-SG strips. For HMDP and DMSA, the 
strips were then developed in methyl ethyl ketone as mobile phase, and for MIBI, the strips were 
developed in NaCl 0.9%.  Under these conditions, [99mTc]Tc-HMDP, [99mTc]Tc-DMSA and [99mTc]Tc-
MIBI remained at the origin and the impurity (pertechnetate) migrated with the solvent front. After 
developing, each strip was first scanned on the Veenstra VCS-203 TLC scanner using a low energy 
collimator with energy window range from 135 to 145 keV. The scan time was 60 seconds and 
background counts were subtracted. Within 5 minutes thereafter the strip was cut in 2 pieces at 4 cm 
from the origin.  The radioactivity from each portion of the strip was counted for 1 minute with the 
RadEye B 20 counter which is a multipurpose survey meter with gamma energy range from 17 keV to 
3 MeV (measurement range from 0 to 500 kcps). Each strip was placed flat in the bottom of a 10 cm 
deep container and the counter placed at the top of the container to ensure that counting geometry was 
the same for all samples. Each count rate reading was recorded with background count rate subtracted.  
From these values, the percentage of radiochemical purity of each strip was calculated.  
4. Validation studies 
The methods for validation of determination of RCP of the current study followed international 
guidelines from the United States Pharmacopeia (The United States Pharmacopeial Convention <1225> 
2008), and the EDQM Guide (2018). Parameters used include accuracy, precision repeatability, 





quantitation. Note that specificity of chromatographic methods depends on the chemical separation of 
compound and impurities. In the validation of the radioactive counting method, this parameter is thus 
not relevant. 
4.1. Accuracy 
Mean RCP values from three replicates of each sample were determined as well as the coefficient of 
variation (CV). The accuracy criteria for the radiopharmaceutical component were met when the mean 
of the standard method differed by not more than 1.5% from the mean value of the proposed method. 
4.2. Repeatability  
The repeatability precision was assessed with five replicates of a spiked sample and the relative standard 
deviation (RSD) was calculated.  
4.3. Intermediate precision 
The intermediate precision was determined by repeating at two different time points (3 h between the 
tests), the chromatography of 5 replicates of spiked samples performed by 2 different operators, 
quantifying distribution of activity on the strips using the two different counting systems. Mean RCP 
values and RSD were calculated. The statistical evaluation by ANOVA of the complete data set where 
results are grouped by each operator, each time point and instrument were analyzed with acceptance 
criteria stating no significant difference at 95% CI (P≥0.05). 
4.4. Linearity 
To test the linearity, the response of the survey meter to Tc-99m was evaluated. A 5 MBq point source 
of Tc-99m was repeatedly counted over a period of 27 hours. The measured count rate was plotted 
against the calculated activity of the point source. In addition, chromatography of three replicates from 
each spiked sample were performed and the chromatograms were read with both the scanner and the 
counter for RCP determination as described above. The linearity results include the equation from the 
linear regression obtained from a plot of % RCP determined with the counter (proposed method) against 





Figure 3.1 Illustration of the robustness test methodology  
(reading with counter at normal position and at 5° angle) 
radiopharmacy), its slope, the correlation coefficient and Y intercept. As acceptance criteria, the slope 
should be close to 1, and r2 ≥ 0.99 
4.5. Robustness 
The robustness of the chromatography counting method with the RadEye B20 counter was evaluated by 
comparing the variation of count rates of five replicates of a spiked sample of MIBI. The pairs of strip 
sections were read with the counter in slightly different positions, i.e. one in the normal reading position 
and the other section with the counter at an angle differing 5° from the normal position (figure 3.1). 
Mean RCP from each set of counts and RSD were calculated. ANOVA was used to check if there were 
any significant differences between the groups. Acceptance criteria are RSD<5% and P≥0.05.  
 
 








4.6. Limit of detection and limit and quantitation 
The limit of detection of the RadEye B20 counter was evaluated by counting a blank (strip with no 
analyte) twenty times with the counter and calculating the mean of blank counts plus 3 times the standard 
deviation of the blank. The limit of quantitation was calculated as the mean of blank counts plus 10 








Complete results are shown in tables and figures. 
1. Accuracy  
Samples with RCP between 78% and 100%, with activities between 2 and 3 MBq were spotted on the 
TLC plates. The mean RCP of triplicate analyses at each sample RCP level from reading of both 
instruments for the 3 radiopharmaceuticals are shown in table 3.1. 
Table 3.1 Accuracy of the proposed method for the 3 compounds 
DMSA %RCP 
Mean ± CV 
MIBI %RCP 
Mean ± CV 
HMDP %RCP 
Mean ± CV 
Scanner Counter Diff Scanner Counter Diff Scanner Counter Diff 
99.7±0.1 99.5±0.1 0.2 99.3±0.4 99.2±0.1 0.1 99.9±0.0 99.4±0.2 0.5 
99.2±1.1 99.2±0.1 0.0 98.5±0.4 98.8±0.7 0.3 97.8±1.0 98.0±1.0 0.2 
92.0±1.7 91.8±1.1 0.2 91.3±3.7 90.6±3.0 0.7 96.6±1.0 95.2±0.9 1.4 
87.9±1.6 88.1±1.3 0.2 84.7±0.6 86.0±2.0 1.3 87.1±1.2 86.28±1.1 0.8 
82.9±0.8 81.9±1.5 1.0 78.9±5.0 78.4±7.0 0.5 82.0±0. 6 82.07±0.8 0.1 
N=3; Diff: difference between RCP from scanner and counter for each product; CV: coefficient of 
variation 
2. Repeatability precision  
The RSD for 5 replicates of spiked samples for the three products from both devices varied between 







Table 3.2 Accuracy of the proposed method for the 3 compounds 
 DMSA 
 




 % RCP Mean ± RSD 
HMDP 
 
% RCP Mean ± RSD 
Scanner  Counter 
 
Scanner Counter Scanner Counter 
RCP 
 
83.1±0.6 83.4±0.8 79.7±1.7 80.9±1.4 82. 0±0.7 82.0±0.6 
Impurity 16.8±3.6 16.6±4.2 19.1±4.3 19.02±6.1 18. 0±3.1 17.9±0.5 
 
n=5; RSD: relative standard deviation 
 
3. Intermediate precision  
Results from the method performed by different operators at different time points for the three products 
gave RCP range from 78.3% to 83.4%, impurity ranged from 16.8% to 23.3%, highest RSD value 6.1 













Table 3.3A Intermediate Precision results: Different Operators  
(n=5, acceptance criteria P≥0.05) 
Spiked 
samples 










Scanner RCP 83.1±0.6 81.6±0.8 3.1 
Scanner Imp 16.8±3.6 18.1±2.9 0.7 
Counter RCP 83.4±0.8 82.5±0.7 0.5 





Scanner RCP 79.7±1.7 79.8±1.0 1.1 
Scanner Imp 19.1±4.3 19.6±4.9 0.6 
Counter RCP 80.9±1.4 80.3±0.7 0.8 





Scanner RCP 82.0±0.7 81.6±0.9 0.4 
Scanner Imp 18.0±3.1 18.0±4.7 0.4 
Counter RCP 82.4±0.6 82.3±0.5 0.2 










Table 3.3B Intermediate Precision results: Effect of Time  
(acceptance criteria ANOVA P≥0.05) 
Spiked 
samples  
Device Time 1 mean 
%RCP±RSD 








Scanner RCP 83.1±0.6 78.32±0.8 5.8 
Scanner Imp 18.8±3.6 20.12±4.5 3.2 
Counter RCP 83.4±0.8 76.7±1.4 11.8 







79.7±1.7 77.2±1.1 2.6 
Scanner Imp 19.1±4.3 22.6±4.5 3.4 
Counter RCP 80.9±1.4 78.2±0.6 2.5 





Scanner RCP 82.0±0.7 79.1±1.1 2.5 
Scanner Imp 18.0±3.1 19.9±4.4 1.3 
Counter RCP 82.04±0.6 78.3±0.9 3.8 
Counter Imp 17.9±0.5 21.6±3.4 3.8 
Note: Same operator at different times; n=5; Imp: impurity 
 
4. Linearity  
The response of the counter to Tc-99m activity ranging from 0.2 MBq to 5 MBq is shown in figure 2.2. 
The regression curves for values obtained with the survey meter against the scanner results for each of 
the radiopharmaceuticals are shown in figure 3. All values of r2 were above 0.99 and all slopes  











































Counter response versus Tc-99m activity





































































Figure 3.2 Response of the counter for Tc-99m activity 
Figure 3.3 Linearity of the proposed method for the 3 products, counter response  





5. Robustness  
Results from 5 replicates of a spiked MIBI sample with one part counted with slight deviation in 
counter position compared very well with those obtained with the counter in the normal position.  
 
Table 3.4 1Robustness of the counter 
 %RCP Mean ±RSD %RCP Mean ±RSD %RCP Mean ±RSD 
Change counter at normal position 
for both parts 
counter tilted 5° for the strip 
section containing the 
impurity 
counter tilted 5° for the 
strip section with the 
bound compound 
MIBI (n=5) 91.5±1.0 91.8±2.6 (P=2.9*) 91.9±2.3 (P=2.4*) 
*  P values for ANOVA of the respective RCP compared to RCP obtained with the counter in the 
normal position 
 
6. Limit of detection and limit of quantitation 
The results from twenty counts of the blank sample (n=20) gave 0.6 counts per second as a mean value 
of the blank with standard deviation of 0.1, for a LOD value of 0.9 counts per second. The calculated 








1. The importance of method validation 
Recommended analytical methods are supplied with package inserts from radiopharmaceutical kits and 
by pharmacopoeial monographs. In radiopharmacies with limited funding, it may be difficult to follow 
the recommended analytical methods due to lack of adequate equipment and limited availability of 
consumables. Other disadvantages of many of the recommended methods include the time required to 
complete the tests, which delays administration of the short-lived products to patients, and use of 
relatively large volumes of solvents when solid phase extraction (SPE) or HPLC are used (Seetharaman 
et al 2004). Thus, there is a clear need for practical, simple, faster (Hammes et al. 2004; Mihon et al. 
2016) and low-cost methods. Any alternative methods should be validated prior to use (Leonardi et al. 
2012). 
The current study describes the validation of a cost-effective quantification method for instant thin layer 
radiochromatography strips using a counting system (RadEye B20) available at YGH, cross-validated 
with a routine method used at the GMP compliant radiopharmacy at UMCG.  
In the current work, the validation parameters prescribed by the ICH (The United States Pharmacopeial 
Convention <1225> 2008), i.e. linearity, precision, intermediate precision, accuracy, assay range, 
method robustness, limit of detection and limit of quantitation were all included for each of 3 SPECT 
radiopharmaceuticals commonly used at YGH (HMDP, DMSA, MIBI).  
2. Standards and Sampling 
In validation of analytical methods, reference standards are generally used for comparison. Certified 
reference standards for 99mTc impurities do not exist in the radiopharmaceutical industry due to the short 
half-life and short shelf life of the radiolabeled complexes as well as absence of a stable isotope of 
technetium. In our study, samples containing varying concentrations of 99mTc-RP were obtained by 
spiking with adequate quantities of sodium pertechnetate and measured with a validated method for 
comparison with the proposed alternative counting method. Seetharaman et al. used a similar approach 






Accuracy can be described as being as near as possible to the expected value. For the experiments in 
this study, we used a similar approach to Mambilima, comparing differences between values from 
standard to proposed methods (Mambilima 2016). We calculated the difference between RCP mean 
value of the standard method and the method of study for the three radiopharmaceuticals at each RCP 
level after spiking with pertechnetate. All differences in RCP were smaller than 1.5%, confirming the 
method of study met the accuracy criteria. Different approaches have been used in the literature. Mihon 
et al. used the percentage recovery within a predetermined specified range to demonstrate the accuracy 
of the method he proposed (Mihon et al. 2016), while Leonardi et al. in 2012 used the RSD value of the 
mean percentage recovery to validate the accuracy of their method (Leonardi et al. 2012). As we used a 
TLC method here, the recovery parameter is not relevant, because all used sample material will remain 
present during the analytical procedure, which is not the case for methods using chromatography 
columns like HLPC.  
In this study HMDP, DMSA and MIBI accuracy analysis met the acceptance criteria at the five RCP 
levels tested. Thus, for the three radiopharmaceuticals the comparison of respective results obtained 
from the two counting systems is good. This indicates that the proposed counting method using the 
RadEye B20 counter is demonstrated to be as good as the Veenstra VCS-203 TLC scanner. 
4. Precision 
Precision can be defined as the closeness of measurements to each other. In contrast with accuracy, no 
relation is investigated between the result and the expected result, or true value. The validation of 
precision in the current work was twofold: firstly, we evaluated repeatability with five replicates of a 
spiked sample for each product. The RSD values of the impurities were much lower than acceptance 
value 15%. It should be noted that for RCP measurements (i.e. the active pharmaceutical ingredient or 
radiopharmaceutical compound) such a high RSD value is not acceptable.  The proposed method using 
the RadEye B20 counter is regarded as precise. Secondly, we did intermediate precision tests by the 
evaluation of the method using different operators, and analysis at different time points, and found no 





previously developed by Chen et al. (Chen et al. 1993) to a simpler method developed using a solid 
phase extraction cartridge (Seetharaman et al. 2006). Even though our survey meter is a relatively simple 
piece of equipment, these results encourage us to advocate the use of the RadEye B20 counter, especially 
in a low-cost setting.  
5. Linearity and range 
The range of radiochemical purity between approximately 80% and 100% used in the study was chosen 
in order to include RCP values recommended by manufactures for patient use (95% to 100%) and to be 
in accordance with ICH and pharmacopeia recommended minimum of five concentrations in the range 
from 80% to 120 % for finished products or assays of drug substances (The United States Pharmacopeial 
Convention <1225> 2008). Our samples contained approximately 2 to 3 MBq/5 µl. 
To prove linearity, the analytical method should exhibit proportionality to the concentration of the 
analyte at the chosen range; r2 should be determined as well as the equation and slope of the regression 
line. We studied the response of the RadEye B20 counter to Tc-99m radioactivity. Linearity was 
demonstrated between 0.2 and 5 MBq. As the maximal amount of counts expected for QC strips is much 
lower than the maximum of the range of the RadEye B20 counter, which can count up to 500 kcps 
according to its specifications, we expect no dead time problems using our method. 
6. Robustness 
Parameters such as mobile phase composition, and ambient temperature influencing the stationary and 
mobile phase flow are typically used to evaluate robustness, especially for HPLC methods (Mihon et al. 
2016). In this work, we evaluated the suitability of a counting system, which is independent of chemical 
separation. Careless positioning of the survey meter might lead to differences in counting geometry 
between the two parts of a chromatography strip. Based on the possibility of slight differences in 
counting position of the counter, the robustness of the counting system was checked by comparing 
counts with a correctly positioned counter against a slightly tilted counter. No significant differences in 
count rates were demonstrated, so the method could withstand at least a small variation in positioning 





7. Limit of Detection and limit of quantitation 
Some authors argue that limits of detection and of quantitation are not required for RCP determination 
with thin layer radiochromatography. Todde et al. indicate that LOQ as usually included in validation 
studies, may not be relevant where the RCP is determined as a ratio between areas or counts, and no 
absolute quantitative measurement is required to be performed (Todde et al. 2014). Seetharaman et al. 
(2006) state that determination of LOD and LOQ can be omitted as only products with RCP values 
higher than 90% are used clinically. It is however important to know if the counting device is able to 
distinguish the lowest expected or clinically meaningful impurity activity from background counts.  
Tc-99m products are usually required to have a RCP of 90 or 95%, i.e. not more than 5% of impurities 
may be present. Exact quantification of impurities larger than 2 % may not be mandatory, as it will not 
affect the acceptance of the product. Calculated from our linearity measurements, 2% of our 5 MBq 
samples would give a count rate of approximately 80 cps, or 50 times the LOQ of the survey meter. 
Looking at the calibration curve, uncertainties are present in the lower range of radioactivity. We think 
that small impurities will rather be overestimated than underestimated. Thus, the survey meter can be 
used, but care should be taken not to use very low amounts of Tc-99m, as impurities might then be 
below the LOQ. 
8. Specificity 
The specificity of chromatographic methods depends on the separation of different chemical entities, 
e.g. the active pharmaceutical ingredient and any impurities. For HPLC, this means that the peaks of the 
different chemical entities should be clearly separated. In our evaluation of the method of quantification 
of the distribution of radioactivity, the chemical separation was done with thin layer chromatography, 
and the same strip was then used for both counting methods. We therefore did not include specificty in 








Guidelines for analytical method validation as presented by international regulatory bodies and national 
authorities (e.g. ICH, FDA) and described in available literature, usually do not provide much 
information for radioanalytical methods such as radio-TLC (ICH Q2R1, EMEA 2006). A notable 
exception is the Guide published by the EDQM in 2018 which does address validation of analytical 
methods for radiopharmaceuticals. Using internationally recommended parameters, we validated our 
proposed method by comparison with a validated method routinely used in a GMP unit.  
10. Limitations 
Limitations of this study include the non-availability of reference standards for Tc-99m labelled 
compounds since there are no stable isotopes of technetium (Todde et al. 2014). The range over which 
the linearity curve for the survey meter was determined, includes typical activities for sample drops used 
for RCP analysis of Tc-99m radiopharmaceuticals with iTLC, but should be extended at the lower end 
to unequivocally include activities expected in impurities representing 0.5% of the sample. Furthermore, 
the linearity measurement with the survey meter for Tc-99m should be extended to include higher 
activities if radiopharmaceuticals with higher radioactivity concentrations are to be analysed. 
In validation studies, sample preparation should be done very carefully, and effects like possible 
adhesion of impurities to containers used in preparing samples should be considered in the design of the 
tests. Furthermore, spiking samples with pertechnetate may result in additional labeling of the Tc-99m-
radiopharmaceutical, which may cause an additional uncertainty in the outcome of the experiments.   
 
Conclusion 
Compared to the standard method, our alternative method was linear, accurate, specific in the range of 
product concentrations internationally recommended for patients, precise, and robust. The value of the 
successful validation of the proposed method is twofold: Firstly, it has increased the awareness of the 
importance of validation among staff in our unit, and secondly, a cost-effective method is now available 
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Abstract  
Background: Environmental control is of the utmost importance to protect radiopharmaceuticals 
against microbial contamination. The Department of Nuclear Medicine at Yaoundé General Hospital in 
Cameroon has introduced a quality control program including passive air sampling. This paper evaluates 
the trends of air quality monitored by settle plate exposure over the year 2017. 
Sampling was performed by positioning opened tryptic soy agar plates for 2 to 4 hours at six 
predetermined locations where radiopharmaceuticals are prepared and dispensed, either during work, 
or while work stations were not used (“rest”) After exposure the plates were incubated at 30 to 35 
°C for 72 hours and the number of colony forming units per hour was determined. Based on the GMP 
grade of the sampling location and the corresponding limits recommended by the European 
Commission, the percentage of settle plate results exceeding the limit were recorded and 





environment were introduced after 6 months. Post intervention sampling evaluated the effect of the 
interventions using Fisher’s two-sided exact test (P<0.05). 
Results: At each site, 77 samples at rest and 40 samples during work were collected before intervention, 
versus 76 samples at rest and 33 samples during work after the intervention. The reduction in percentage 
of plates exceeding the action limit were as follows: In the closed cabinet at rest: 55%; during work: 
42%. In the LAF at rest: 14%; during work: 11%. In the open bench area at rest 45% and during work 
45%. On the lab floor, the decrease was 6% at rest and 10% during work. The microorganisms identified 
were Staphylococcus epidermidis, other gram positive bacteria, and Candida species. Significant 
improvements were found at all sample locations with all p ≤0.05. 
Conclusion: Passive air sampling was implemented and it was confirmed that subsequent simple 
interventions led to a marked improvement in the air quality. 
 







Radiopharmaceutical injections are, like any other injectable product, in need of special protection, as 
potential microbiological contamination could harm the patient. Therefore, the environment in which 
sterile injections are prepared should be controlled, clean and free of microorganisms. Monitoring results 
help to alert the staff about the performance of the equipment, procedures, and the operators’ techniques 
and skills, and it can guide effective preventive actions. The real value of a microbiological monitoring 
program lies in its ability to confirm consistent, high quality environmental conditions at all times.  
To assess the level of microbial contaminants or other harmful substances and control the 
microbiological status of working environments for aseptic processing, a range of sampling methods are 
available (The United States Pharmacopeial Convention <1116> 2013). These include particle counting 
and methods monitoring growth of microorganisms. 
Three different microbial contamination risk levels are defined in the literature (The United States 
Pharmacopeial Convention <797> 2012). If products are compounded from sterile commercial drugs 
using sterile devices and where procedures involve only a few basic steps in a closed system with simple 
aseptic transfer and manipulation, the procedure is regarded as low risk. The medium risk level involves 
areas in which multiple sterile commercial products are prepared, complex aseptic manipulations are 
done and procedures cover a long period of time. Quality assurance procedures include all steps required 
at low risk level, as well as more challenging tests like media fill tests. When products are prepared from 
non-sterile ingredients, compounded using non-sterile devices prior to terminal sterilization, or products 
are exposed to conditions worse than class A air quality for longer than an hour, the procedures are 
regarded as high risk. Radiopharmacies working with technetium-99m generators and commercial kits 
work with closed systems which carries a relatively low risk, but as multiple doses are dispensed from 
the kits over the span of several hours, the work should probably be categorized as medium risk. 
According to the IAEA, these procedures should therefore be performed in a Grade A clean air 
environment (e.g. a vertical laminar air flow unit or isolator), and the room air should also meet class C 
or D requirements and these environments should be subject to regular microbiological monitoring 





Specific locations for air sampling are determined considering the proximity of the exposed products to 
the environment. Using pre-defined sampling sites allows comparison of the level of contamination of 
an area or site over time (Sutton S 2015). Microbiological sampling sites are best selected considering 
human activity during production operations, as contamination is strongly related to location, movement 
and behaviour of personnel within a critical zone. Areas where monitoring is critical are those related to 
airborne contamination, entry points where materials and equipment move from areas of lower to higher 
classification, and areas around doors and airlocks.   
The logical step following results of environmental monitoring which exceed recommended limits, is 
the introduction of corrective and preventive actions (CAPA). Personnel flow and behaviour, operations, 
and materials are factors that could be analysed to try to pinpoint the root source of contaminants (WHO 
November 2012). 
The work reported in this paper concerns a radiopharmacy unit that is not GMP compliant and that is 
only able to perform passive air sampling. Nevertheless, the unit strives to comply with Good 
Radiopharmaceutical Practice (GRP) recommendations, and has recently implemented environmental 
monitoring by passive air sampling. This paper describes the trends of air quality monitored by settle 
plate exposure over the year 2017 at Yaoundé General Hospital (YGH) in Cameroon, and the effect of 







Passive air sampling was performed in the YGH Radiopharmacy by positioning opened tryptic soy agar 
plates (TSA, diameter 90 mm) for 2-4 hours at locations where radiopharmaceuticals are prepared and 
dispensed. The sampling was carried out both when there was no work activity in the area (“at rest” or 
“resting”) and during work activity (“during work” or “working”) in predetermined areas in a closed 
cabinet (CC) (2 sites), laminar air flow cabinet (LAF) (2 sites), on the open bench (OB) (1 site) and the 
floor at the radiopharmacy entrance (F) (1 site). After exposure the plates were incubated at 30 to 35 °C 
for 72 hours. The observed number of colony forming units (CFU) were corrected to reflect a 
standardised 4-hour period. Where possible, plates were sent to the microbiological unit for 
identification of microorganisms. The total number of measurements for each sampling site during the 
6-month interval was determined. Based on the recommended GMP grade of the sampling location and 
the corresponding recommended limits, the percentage of settle plate results exceeding the limit was 
recorded.  
Several interventions aimed at improving cleanliness of the Radiopharmacy environment were 
introduced after 6 months. Operator training was scheduled for once a month. Wall and window cleaning 
on a regular basis were introduced. All syringes were removed from cardboard boxes and placed in 
plastic containers prior to transfer into the room. Cotton swabs were replaced with gauze, sterile gloves 
were introduced for any operation performed in the radiopharmacy rooms and all the lab coats used in 
the radiopharmacy were sterilised on a regular basis. Easy to clean plastic shoes were introduced for 
each operator at the entrance of the radiopharmacy. For any cleaning operation in the radiopharmacy, 
sterile water is now used rather than tap water. At the end of each week, the CC and LAF are sterilised 
by drops of 10% formol on gauze and remain exposed for the whole weekend.   
After the introduction of the changes, samples were collected for six months to evaluate the effect of the 
change. The number of plates exceeding the limit recommended by the European Commission GMP 
Guidelines (2008) for the corresponding class (at rest and during work before and after intervention) 
was recorded and the percentage of reduction in exceeding plates calculated. To assess the statistical 





using STATA Statistics version 15.1 (copyright 2017 StataCorp, Texas 778). P values of less than 0.05 
were considered statistically significant. 
Results 
A total number of 1356 plates were collected; 702 before the intervention and 654 plates after the 
intervention. 77 samples at rest and 40 samples during work were collected at each site before 
intervention, versus 76 samples at rest and 33 samples during work after the intervention. The results 
from all sampling sites exhibit a clear improvement both at rest and during work with data of the 
reduction in exceeding plates ranging from 6% to 60%. The lowest percentage of reduction was found 
on the floor (6% at rest and 10% during work) while the highest reduction was recorded in the closed 
cabinet (between 49% and 60%). All the results are represented in tables 4.1 to 4.3 below. 
In total, only 9% of settle plates before intervention were not contaminated, compared to 53% after 
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Table 4.2 Fisher’s two-sided exact test of data from plate exposure  
before versus after corrective action 
Area Rest Work 
Closed cabinet F=0.14 F=0.01 
LAF F=0.40 F=0.02 
Open bench F=33.42 F=3.60 
Floor F=12.82 F=4.74 
P was always <0.05 
 
 
Table 4.3 Microbial trends in the closed cabinet in 2017 
















N 85 99 0 11 33 44 12 58 
%N 72% 84% 0% 9% 30% 40% 11% 53% 
Total 117 117 117 177 109 109 109 109 









Classification and maintenance of an environment depend on a number of factors including the premises, 
equipment characteristics, operating staff’s clothing and behaviour, and cleaning procedures (Todde et 
al. 2017; Kastango and Bradshaw 2004, IAEA 2008 (b)). According to Todde et al. (2017) the 
qualification of classified environments in radiopharmacies can be difficult, due to lack of 
instrumentation and skills. The trends of microbial contaminants in the current study revealed the 
presence of viable microorganisms at all sampling sites. The general overview of all sites exhibits higher 
concentration of viable microorganisms during work than when there was no work performed. An 
exception was the slightly reversed tendency in the closed cabinet where there were more viable 
microbes at rest than during work before intervention. This pattern persists after intervention. The most 
likely explanation of the situation is the position of the cabinet close to the entrance of the radiopharmacy 
in an area of high human traffic, and construction work around the building. The LAF which is further 
removed from the entrance in a more sheltered position is less exposed to traffic and dust, which is 
reflected in lower microbial contamination values. In addition, the LAF is used less frequently and by 
more experienced staff members than the closed cabinet. That the least reduction in exceeding plates 
was found in the floor samples is not surprising as it is difficult to maintain a clean environment close 
to an entrance door.  
Although target limits for passive air sampling are recommended (Elnour et al. 2018), there are 
discrepancies regarding sampling procedures including nutrient media, incubation condition (Gordon et 
al. 2014), and sampling sites. The reasons for such diverse methods could arise from the fact that critical 
sampling points depend essentially on the setting and the locations posing microbiological risk to the 
product (The United States Pharmacopeial Convention <1116> 2013). Authors refer to different 
environments, thus methods and limits may differ. Diverse nutrient media are used. Elnour et al. in 2018 
used blood agar nutrient media, Napoli et al. (2012 (a) and (b)) used TSA for active air sampling and 
maltose salt agar for passive air sampling for their experiment. The medium should be selected according 
to target or expected microorganisms to obtain optimal growth. Naik and coworkers estimated microbial 





of air sampling plus assessment of air quality in an operation theatre using blood agar plates (Naik S et 
al. 2018, Tshokey T et al. 2016). We used TSA nutrient for our passive air sampling because it is easily 
available, and low-cost. All-purpose TSA containing enzymatic digests of casein and soybean meal is a 
non-selective nutritious medium for a wide range of organisms, providing enough nutrients to allow a 
variety of microorganisms to grow. It is in fact recommended for microbiological environmental 
monitoring in pharmaceutical facilities by the USP (The United States Pharmacopeial Convention 
<1116> 2013). Air sampling is commonly done both during work when contamination is expected to be 
higher, as well as when there is no activity in facilities (Napoli et al. 2012 (a), Caggiano et al. 2014).  
Extensive interventions, including reduction of activities involving traffic around the environment, 
training on personnel hygiene and behaviour in the laboratory, and introduction of sterile coats and 
radiopharmacy dedicated shoes that can easily be cleaned, helped to improve the situation, with 
significant differences in all sample locations. All these interventions were easy to implement and did 
not involve major expenses. A continuous assessment program is currently in place to monitor and 
evaluate the contaminant level at each sampling site on a regular basis.  
Microbiological trending is quite critical for facilitation of process improvement.  It is a supporting tool 
for several aspects including illustration of the level of compliance, the efficacy of sanitization, and the 
gowning process. Moreover, it helps in understanding which microorganisms pose a risk and proactively 
preventing future environmental problems (The United States Pharmacopeial Convention <1116 > 
2013; Elsinga et al. 2010). According to Sandle, microorganisms primarily encountered in cleanrooms 
are gram-positive bacteria associated with human skin (Sandle 2011). We indeed found mostly gram-
positive bacteria including Staphylococcus in our study. There was a remarkable reduction of 
Staphylococcus epidermidis and other gram-positive bacilli after the intervention. The reduction of the 
number of bacterial colonies and increase in number of sterile samples illustrate the effectiveness of the 
implementation of our interventions to improve cleanliness. The presence of Candida species after 
implementation of interventions may be due to presence of construction workers moving in and out of 





In GMP-compliant facilities, the risk in areas in which radiopharmaceuticals are normally prepared is 
primarily related to human errors. In a non-compliant facility, which is not well-designed, lacks clean 
air supply, and with poor maintenance of cabinets and filters, products are exposed to other risks arising 
from the environment in the radiopharmacy unit. While our results show a marked reduction in 
contamination risk, the internationally recommended levels of clean air have not been achieved and 
more effort is still needed, especially regarding facility design. 
 
Conclusion 
Passive air sampling was implemented and it was confirmed that interventions led to an improvement 
in the air quality in the Yaoundé General Hospital radiopharmacy unit. Continued efforts should be 
made for the sustainability of the quality of products prepared. Other low-income radiopharmacy units 
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Abstract  
Passive microbiological air sampling is a relatively simple and affordable method for evaluation of air 
quality. In this paper, air sampling results from two African radiopharmacies (designated I and II) with 
different economic backgrounds were evaluated.  
In the two African radiopharmacies, settle plates were exposed at predetermined locations in comparable 
working areas and then incubated. The number of colonies per hour of exposure were determined. Based 
on recommended limits for the respective areas, results from the two units were compared and data from 
routine settle plate counts from a Good Manufacturing Practice-compliant European facility 
(radiopharmacy III) were used as standard. 
Radiopharmacy I, in a developing country, had the highest incidence of results exceeding recommended 
limits. Results from air sampling at radiopharmacy I differ significantly from those from radiopharmacy 





For radiopharmacies unable to afford the systems required to provide a clean room, it is difficult to reach 
the recommended levels of air quality. A validated class II LAF cabinet which is well maintained and 
used correctly, can play an important role to provide microbiologically clean air in such 
radiopharmacies. 









Healthcare facilities can harbour many microorganisms, including environmental opportunistic and 
airborne pathogens. For this and many other reasons, a consistent quality assurance program, involving 
a combination of validated processes and well-established tests, is a key factor in pharmaceutical 
production. Regulatory bodies and pharmacopoeias stipulate comprehensive standards (Food and Drug 
Administration 2004, EDQM 2018, The United States Pharmacopeial Convention <797> 2012), in order 
to ensure patient safety. The sterility of radiopharmaceuticals depends on the quality of air of the unit in 
which they are prepared and dispensed (Elsinga 2010). Due to the risk of product contamination and the 
negative impact thereof on patient safety, special focus is placed on control of the environment. 
Continuous environmental monitoring methods and well-designed processes are practical aspects to 
consider for mitigation of the risk of contaminating products.  
Air quality monitoring must ideally comprise different techniques implemented continuously for a 
constant overview of microbial levels throughout the whole facility. Recommended monitoring 
techniques include particle monitoring, active air sampling, surface contact plates or swabs, operator 
fingerprints and settle plates or exposure plates (Beaney 2016, The United States Pharmacopeial 
Convention <825> 2019). According to GRP guidelines it is best to monitor both viable and non-viable 
particles. Constant monitoring helps pinpointing high risk areas which assists in addressing the problems 
in a targeted manner. Information gathered by regular monitoring will help to respond timeously if trends 
approaching limits are observed, enabling preventative measures.   
Studies in literature describe different procedures for air monitoring. The choice of the optimal method 
could depend on the availability of equipment or consumables, difficulty of procedures or possible ways 
to address the relevant issue on site. An example is passive air sampling using settle plate exposure in 
identified sites. Diverse media are used (tryptic soy agar (TSA), blood agar, Sabouraud dextrose agar), 
and incubation temperatures and periods vary. Some authors sample while the area is not used and others 
both when the sites are used and when they are unused (Gordon et al. 2014, Naik et al. 2018, Tshokey 





Guidelines for radiopharmacy practice in many countries prescribe complex facilities, especially air 
handling units, and extensive quality assurance and documentation requirements. In developing 
countries, these guidelines are currently not always met, due to several factors, including the high cost 
of facilities and equipment. In numerous countries in Africa, enforcement of the international guidelines 
would lead to closure of radiopharmacies, and consequently, loss of Nuclear Medicine services, as they 
depend on radiopharmacies to provide the required diagnostic and therapeutic products.  
Good Manufacturing Practice (GMP) and Good Radiopharmacy Practice (GRP) recommendations 
highlight that, in order to prevent microbial contamination of products, Tc-99m radiopharmaceuticals 
should be radiolabelled and dispensed in a laminar air flow cabinet (LAFC) situated in a grade C clean 
room, or an isolator in a grade D clean room. Radiopharmaceuticals are prepared and dispensed under 
different circumstances in the three radiopharmacies included in this study. Radiopharmacy III in 
Netherlands is a well-equipped GMP compliant unit. Radiopharmacy II is relatively well-equipped and 
has a well maintained dedicated shielded LAFC, but located in a room that does not meet clean room 
standards, while radiopharmacy I has a closed cabinet that has not been subjected to regular maintenance 
and is located in an unclassified room.  
Implementing good practice with limited funding remains a challenge faced by many sub-Saharan 
radiopharmacies. The question arises if we can produce safe radiopharmaceuticals even when the facility 
does not meet regular requirements for structure and equipment. How does a sub-optimal facility impact 
on air quality in critical areas? If the level of air quality does not meet the recommended standards, are 
structural improvements always essential?  
This work studies outcomes of passive air sampling in the radiopharmacies of two large teaching 
hospitals in Cameroon and South Africa with economic status regarded respectively as lower middle 
income and upper middle-income countries. The results from a GMP-compliant radiopharmacy in a 








The passive air sampling method in the two African radiopharmacies entailed exposure of tryptic soy 
agar plates (TSA, diameter 90mm) for 2 to 4 hours at locations where radiopharmaceuticals are prepared 
and dispensed. The plates were incubated at 30 to 35°C for 72 hours and colony forming units were 
counted. The observed number of colony forming units (CFU) were corrected to reflect a standardised 
4-hour period. Routine sampling at radiopharmacy III was performed during the work session in the 
relevant areas, while at radiopharmacies I and II, samples were collected both during work (working) 
and when the LAF cabinet or closed cabinet was not used (resting). The colony counts were evaluated 
according to limits described in the EU classification for the relevant areas in radiopharmacies (IAEA, 
2008, European Commission 2008). Depending on the type of operation performed, and whether 
samples were collected at rest or during work and based on the recommended limit for microbes present 
in sampling sites, the number of plates exceeding the limit were recorded.  
Data from radiopharmacy I and radiopharmacy II were compared using Fisher’s two-sided exact test. P 
values of less than 0.05 were considered statistically significant. Data of routinely collected samples 
from radiopharmacy III served as a standard of air quality monitoring.  
 
Results 
At radiopharmacy I, a total of 654 samples was included in the study, 456 samples collected at rest and 
198 during work. At radiopharmacy II, 875 samples were collected during the period of study (560 
samples during work and 315 samples at rest) in all sampling sites. At radiopharmacy III, 1825 samples 
were collected during work. 
The percentage of plates exceeding the recommended limits in the three centres are represented as 
follows: 
Table 5.1 presents the percentage of the settle plates (including resting and working) exceeding the 
relevant recommended limit during work and at rest in each sampling area. Figure 5.1 shows differences 





between corresponding areas at radiopharmacies I and II are provided in Addendum table A.9. The 
difference was significant in the cabinets where radiopharmaceuticals are prepared and on the open 
bench. In both radiopharmacies, there was no significant difference between the results obtained during 
work and resting (Addendum table A.10). 
 
Table 5.1 1Percentage of total number of settle plates exceeding relevant colony count limits 
 Limits 
(CFU/4h) 
I II III 
Area where RP are 
prepared 
< 1 37% 6% 3% 
Other class A area < 1 12% 7% 2% 
Class C area 50 15% 8% 0% 


























 Figure 5.1 Passive air sampling at the 3 radiopharmacies (RP) 
Legend 
Room 1 (D) Gowning area 
Room 2 (D) Clean room SPECT regular 
Room 3 (C) Clean room for cell labelling 
Room 2 LAF1 (A) forTc99m 
Room 2 LAF2 (A) other radiopharmaceuticals 
Room 3 LAF (A) for cell labelling 
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The current study is part of quality assurance programme monitoring aspects recommended in literature 
(European Commission 2008) to improve microbial safety in two African radiopharmacies. 
Radiopharmacy I started implementing passive air sampling in its radiopharmacy unit during the year 
2017, and after a baseline study implemented corrective actions to improve the quality of air (Ekoume 
2018). The values shown in this study are all after the improvements. 
The highest percentage of colony counts exceeding the relevant limit were seen in radiopharmacy I. Of 
the different areas monitored in radiopharmacy I, the LAF had the lowest number of contaminated settle 
plates. This LAF is located in the quietest area in radiopharmacy rooms with the least human traffic and 
activities. Radiopharmacy II recorded less contamination in all areas. As expected from a GMP-
compliant facility, radiopharmacy III had the lowest number of colony counts exceeding limits at all 
sites.  
The work in radiopharmacies I and II could not be directly compared with the results from 
radiopharmacy III due to differences in the incubation temperatures and times. Radiopharmacy I and II 
incubated the TSA for 72 hours at 30 to 35 °C, while at radiopharmacy III, the plates were incubated for 
48 hours at 32°C (for bacterial growth), followed by 5 days at room temperature to allow fungal growth. 
As neither of the two African radiopharmacies have rooms with clean air supply, many viable organisms 
tended to be present, which could result in a fast overgrowth per plate. Despite the less than ideal 
circumstances of the 3-day incubation at the higher temperature, radiopharmacy I did detect Candida 
species on several settle plates, both in earlier work (Ekoume 2018), and during the current study, 
indicating that the method used was sensitive enough to detect at least some species of fungi. 
Results from the current work highlight existing deficiencies and the need for improvement in design 
and work methods, especially in radiopharmacy I. Recommendations for a new facility were submitted 
and accepted by the hospital management and a maintenance engineer for the unit was recruited to be 





In earlier work, radiopharmacy 1 showed that a number of simple and affordable techniques can lead to 
a marked improvement in the air quality in the area where radiopharmaceuticals are prepared and 
dispensed (Ekoume 2018). Despite these measures, there is still a high incidence of viable 
microorganisms in areas that should, according to international recommendations, meet class A air 
standards. In radiopharmacy II, the LAF dedicated to Tc-99m radiopharmaceuticals fares much better. 
It is worthwhile considering the factors that may contribute to this difference. Although the room in 
radiopharmacy II is not designed as a clean room and does not reach clean room status, the dedicated 
LAF is regularly monitored, cleaned and maintained. Staff members are specifically trained to 
implement correct working procedures in the LAF. All items used in the LAF are disinfected before 
placement in the LAF, and staff wear sterile gowns and sterile, powder-free gloves. A second staff 
member is present in the radiopharmacy to assist with documentation and quality control of the products, 
thus minimising the number of times the operator may have to interrupt and resume tasks inside the 
cabinet.   
Neither of the African radiopharmacies could achieve a level of air quality equivalent to that of the 
GMP-compliant facility, which has a suite of clean rooms with a dedicated ventilation system. Thus 
there remains some risk of microbial contamination of products.  
Despite the fast growth of radiopharmacy, there are no published studies describing air quality 
monitoring in radiopharmacies in Africa. Using a simple and affordable method, the current study 
successfully identified the trends of microbial contamination in the two African radiopharmacies 
included in the study. This study highlights the value of air quality monitoring in the African context.  
Simple measures like additional staff training, improved hygiene measures and reduction of movement 
in the radiopharmacy rooms can contribute to reduce the presence of microbes in the radiopharmacy. 
However, these steps will not reduce the risk of microbial contamination of products to a GMP-
compliant level.  
The best solution is evidently to follow international recommendations, i.e. invest in a clean room 





may not be achievable in developing countries with limited funds to support nuclear medicine and 
radiopharmacy facilities.   
The current work shows that an intermediate option can bring the environment for radiopharmaceutical 
preparation and dispensing almost to the required standard. Working in a validated, well-maintained 
class II LAF cabinet can contribute largely to provide microbiologically clean air. It is important that 
staff is well-trained, uses good cleaning protocols and suitable garments and adheres strictly to working 
protocols in the cabinet. 
 
Conclusion 
The current study successfully investigated the microbiological air quality in two African 
radiopharmacies. It describes an affordable and useful monitoring method that can easily be used by 
other radiopharmacies with limited resources.  
In order to provide the optimal environment with the lowest possible microbial risk for intravenous 
radiopharmaceuticals, laminar air flow cabinets or closed cabinets in clean rooms are recommended. 
When clean rooms are not available, it is difficult to reach the recommended levels of air quality. This 
work shows that correct use of a validated, well-maintained class II LAF cabinet can contribute largely 
to provide microbiologically clean air and can thus play an important role in facilities that cannot afford 
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Abstract 
An affordable approach is applied to evaluate the level of microbial safety for radiopharmaceuticals, 
used in two African Nuclear Medicine units.  Media fill testing (MFT) and fingertip testing (FT) was 
implemented at radiopharmacy I to evaluate staff members’ ability to maintain sterility during 
manipulation of radiopharmaceuticals. The rate of contaminated products as determined by sterility 
testing at radiopharmacy I and II was 1.8% and 0.38% respectively during the period of study. The 
presence of contaminated samples and a comparative study with routine data from a GMP-compliant 
European radiopharmacy III recording 0% product contamination, indicate that more effort is needed in 
both centres. Radiopharmacy I also had a higher rate of contaminated fingertip plates than 
radiopharmacy III. MFT and FT at radiopharmacy I identified problems with implementing aseptic 
technique, understanding of procedures, and the ability of workers to apply learned skills in the unit. 
The skills of a newly recruited staff member were improved through dedicated corrective actions. 
 






With the worldwide expansion of radiopharmacy through the creation of new PET and SPECT units, it 
is important to ensure that good practice is well established in each unit, including small scale production 
facilities (Elsinga 2010). Quality control tests (QC) and quality assurance (QA) programs, including 
validation of methods, are important tools recommended to ensure the quality of products. They provide 
evidence of the suitability of the procedure and help to provide safe final products (Ajay et al. 2012). 
Microbial safety of radiopharmaceuticals remains a relevant topic drawing the attention of scientific 
communities and leading to updating pharmacopoeias (The United States Pharmacopeial Convention 
<825> 2019, IAEA 2016). This aspect of quality assurance involves a range of monitoring parameters 
including sterility testing, microbial environmental monitoring (surface testing, air sampling), and 
process and aseptic technique validation using media fill tests. Periodic sterility testing of 
radiopharmaceuticals, and validation and revalidation of each step of the entire procedure by media fill 
and fingertip testing, are recommended for optimal microbiological safety in radiopharmacy (The 
United States Pharmacopeial Convention <825> 2019, Elsinga et al. 2010, Todde et al. 2017, Lange et 
al. 2015). 
Sterility testing of radiopharmaceuticals is conducted to ensure that a batch of products is free of viable 
microbes (bacteria, yeasts, moulds or any other microorganisms). However, satisfactory results of tests 
indicate only that the examined sample has no contaminating organisms under the conditions of the test. 
This test can be done by inoculating the product directly into appropriate culture media, followed by 
incubation at suitable temperatures. Observation and interpretation of results should be done by a well-
trained operator at regular intervals during the duration of the incubation. Products comply with the 
requirements for sterility if no turbidity develops in the media or if there is no evidence of growth in the 
media. If any growth is found in the media, identification of the microbe and the possible origin of the 
microbe should follow in order to start appropriate corrective action (The United States Pharmacopeial 
Convention <71> 2012). Aspects affecting the sterility of pharmaceutical products include facility 






Aseptic technique validation should be compulsory for any operator involved in preparation and 
dispensing of sterile radiopharmaceuticals. Media fill testing with culture media is used to validate 
pharmaceutical processes. It is adapted to reflect the manipulations carried out by the operators, 
simulating the most challenging and stressful conditions in their duties (The United States 
Pharmacopeial Convention <825> 2019, Sigward et al. 2012, Urbano 2013). Other aspects like cleaning 
and disinfecting the workstation, hand hygiene, garbing as described in the standard operation 
procedures (SOPs), and aseptic technique should also be included in staff qualification.  
As most radiopharmaceuticals are administered intravenously, particular attention should be paid to the 
safety of products prepared and dispensed in radiopharmacies that are relatively poorly equipped and 
funded. In this context, we evaluated aspects of Good Radiopharmacy Practice (GRP) implemented in 
a basic radiopharmacy in Cameroon (named radiopharmacy I hereafter) and a relatively well-established 
radiopharmacy (II) in South Africa. This work evaluates sterility of radiopharmaceuticals prepared at 
radiopharmacies I and II, and the aseptic status of radiopharmaceutical preparation methods and staff 
competence at radiopharmacy I by media fill with fingertip testing. Results of routine tests from a GMP 









1. Sterility testing 
Samples were obtained from routinely prepared Tc-99m radiopharmaceutical (RP) vials containing at 
least 2 ml product after dispensing of the last patient dose. The vials were set aside for sterility samples 
and the Tc-99m was allowed to decay (60-90 hours). Samples were selected to ensure that all different 
kits used in the facility were represented in the sterility test series. A microbiology laboratory operator 
inoculated tryptic soy broth (TSB) with the decayed RP. Inoculated broth was incubated firstly between 
20 and 25 °C for 7 days then at 30 to 35 °C for 7 days and visually monitored for any signs indicating 
microbial growth. 
The rate of contamination was calculated as the number of radiopharmaceuticals contaminated divided 
by the total number of radiopharmaceuticals tested for sterility at the relevant hospital.  
2. Media fill and fingertip testing 
Aseptic process qualification by media fill testing (MFT) or process simulation was done by 4 workers 
involved in the radiopharmaceutical preparation at radiopharmacy I. The test included the facility’s 
existing procedures for cleaning and disinfection, garbing and aseptic technique. TSB was prepared and 
filled as shown in figure 6.1, simulating all the steps currently used for daily radiopharmaceutical 
preparation and dispensing. The protocol was conducted in 6 replicates for operators’ initial 
qualification and repeated in case of failure until successfully completed. Thereafter each operator had 
to repeat the test approximately every 6 months as routine evaluation or requalification. Media fill testing 
was performed immediately after a work period to introduce a fatigue factor. The media were incubated 
and identification of contaminants followed when necessary. Quality control of the media included 
growth promotion tests. All the growth media used were provided by qualified microbiologists from the 
microbiology laboratory in the same hospital.  
TSA (Tryptic Soy Agar) plates were used for gloved fingertip testing of the sterile gloves after 
completion of each media fill. Immediately after the MFT, without disinfecting the gloves, each finger 





the same plate and those from the left hand in the second plate. At the end of each routine test a total of 
5 vials (all shown in figure 6.1) and 2 plates were ready for incubation. For each initial validation 30 
vials and 12 settle plates were collected for incubation. Plates were incubated at 25-30 °C for 3 days and 
vials for 7 days at 20 to 25° C, then at 30 to 35 ° C for additional 7 days.  
The rate of vials contaminated during media filling (number of contaminated vials divided by total 
number of vials filled), the rate of plates contaminated during the fingertip operation (number of 
contaminated plates divided by total number of plates used) and the rate of media fill failure (number of 
tests failed divided by the total number of media fill tests performed) were calculated.  
New staff members who failed the MFT were retrained (theoretical and practical training). For 
completeness, retraining included not only aseptic technique, but also general radiopharmacy skills like 




















The results of sterility testing of radiopharmaceuticals routinely produced at radiopharmacy I are 
summarized in the table 6.1, those for radiopharmacy II in table 6.2. At radiopharmacy III, samples from 
103 SPECT radiopharmaceuticals were evaluated for sterility between 2018 and 2019 and none of them 
presented any growth.  
 
Table 6.1 Sterility test results at Radiopharmacy I over an 18-month period 
Radiopharmaceuticals No of samples tested No of samples showing  
microbial growth 
Pertechnetate (eluate) 81 2 
HMDP 16 0 
MIBI 3 0 
DTPA 7 0 
DMSA 1 0 
Total (5 different 
radiopharmaceuticals) 







Table 6.2 Sterility test results at radiopharmacy II over a 4 year period 
Radiopharmaceuticals No of samples tested No of samples showing  
microbial growth 
MDP 34 0 
MIBI 26 0 
MAA 28 0 
Nanocolloid 12 0 
MAG3 32 0 
Tin colloid 19 0 
DTPA 35 0 
HMPAO 20 0 
DMSA 20 0 
RBC 7 0 
BRIDA 8 0 
Eluate 16 1 
Total (12 different 
products) 








Table 6.3 Radiopharmacy I operators’ media fill and fingertip test results  
(Jan 2017 to Jan 2019) 




A 3 validation 
5 routine 
0% of 115 8% of 46 
B 4 validation 
4 routine 
0% of 140 14% of 56 
C 4 validation 
4 routine 
0% of 140 10% of 56 
D 5 validation 
5 routine 
1% of 175 30% of 70 






Table 6.4 Radiopharmacy III media fill and fingertip test results 
Operator No of tests MFT contamination rate FT contamination rate 
E 1 validation 
10 routine 
0% of 80 vials 28% of 32 plates 
F 13 routine 0% of 65 7% of 26 
G 12 routine 0% of 60 1% of 24 
H 1 validation 
9 routine 
0% of 70 17% of 28  
I 4 routine  0% of 25 12% of 8 
J 1 validation   
8 routine 
0% of 70 21% 0f 28 
K 1 validation 0% of 30 0% of 12 
L 2 validation 0% of 60 21% of 12 
Eight operators currently producing SPECT radiopharmaceuticals were included in the current study at 
Radiopharmacy III. 
 
The operators at radiopharmacy I failed 12 tests from a total of 34 media fill tests performed (mostly 
due to failed fingertip tests) for an overall failure rate of 35%, although only 2 of the 570 filled vials 
(0.3%) were contaminated. At radiopharmacy III, 4 cases of MFT failure were found in a total of 61 
tests done, all due to fingertip test failure. A failure rate of 6% was recorded with 0% of vials 










Quality Control in radiopharmacy has unique challenges due to the short half-life of many radionuclides, 
which does not allow lengthy test procedures like sterility testing prior to use of the products. Working 
in a clean environment and following defined operating procedures like aseptic transfer techniques 
endorsed by retrospective sterility tests on radiopharmaceuticals is essential to ensure their sterility. The 
TSB medium that was used in the current work is a multipurpose medium allowing the growth of a wide 
range of aerobe and fungal microorganisms. 
Sterility data from two different African radiopharmacies was evaluated in this work, and compared 
with results from a large GMP-compliant European unit. Radiopharmacy I serves the Nuclear Medicine 
unit of a teaching hospital in an African country classified as lower middle-income by the World Bank 
(World Bank data 2019). Radiopharmacy I does not have clean room facilities, and due to financial 
limitations, the cabinet in which Tc-99m tracers are prepared and dispensed is not maintained to function 
as a class A clean environment. Radiopharmacy II in a large hospital in an upper middle-income country 
in Africa also does not have a clean room, but the shielded laminar air flow cabinet is well-maintained 
to provide a class A clean air environment for Tc-99m generator elution, kit preparation and dispensing 
of patient doses. Radiopharmacy III meets GMP criteria, with the necessary suite of clean rooms, sterile 
attire and quality management system. This radiopharmacy serves a large teaching hospital in a 
European high-income country. 
For all three centres only preparation and dispensing of products in closed or nearly closed systems are 
included in this study. Normally, the risk of contaminating vials is very low in such situations, as there 
is no exposure of the ingredients or products to microbial risk. The risk is however increased, because 
radiopharmaceutical kits are usually prepared to supply multiple individual doses, and the pertechnetate 
vial is penetrated by needles more than twice during elution and preparation of several kits for the day. 
Thus, Tc-99m radiopharmaceuticals should be classified as medium-risk according to the USP criteria 
(The United States Pharmacopeial Convention <797> 2008, Gurajala et al. 2015). The risk level is 





Sterility is a critical parameter for the safety of radiopharmaceuticals for human use (Boschi A and 
Duatti A. 2019, Statuto et al. 2016) and sterility testing is therefore essential. The existing literature 
suggests contamination rates between 0.86% (Weatherman et al. 2013, radiopharmaceuticals) and 5.2% 
(Trissel et al. 2005, compounded pharmaceutical products). Values obtained in our study from both 
middle-income centres are lower than the rate described by Trissel et al. in 2005. It should however be 
noted that Trissel et al. describe competency evaluation for medium-risk-level compounding procedures, 
which are more complex than most procedures involving preparation and dispensing of Tc-99m 
radiopharmaceuticals. The higher contamination rate at radiopharmacy I compared to radiopharmacy II 
can be ascribed to the difference in status of the facility and equipment.  
The contaminated product in both units originated from Tc-99m generator eluate. Due to the relatively 
long shelf-life of Tc-99m generators and the use of eluates to prepare radiopharmaceuticals for many 
patients each day, this is a cause for concern. Microbial contamination of radionuclide generators could 
theoretically occur in the generator, which is eluted with sterile saline solution one or more times per 
day over a period of approximately two weeks. The generator eluates provide the pertechnetate for 
preparation several different kits in the course of a day, as well as pertechnetate doses for thyroid 
imaging. If contamination occurred in the generator, kits prepared from pertechnetate from that 
generator in the following days would also be contaminated. At both our study sites, no contaminated 
kits were identified. If there is a high risk of such contamination, a simple filtration step using a 0.22 
μm filter could be implemented. Furthermore, according to Sorensen et al. (1977) and Allwood and 
McCarthy (1980), Tc-99m generators are not a favourable environment for microbial life. Another 
possibility is contamination during use of a vial of eluate. With multiple septal penetrations of 
technetium eluate vials during a workday, the possibility of microbial contamination remains a risk, 
even when good aseptic technique is used (Snowdon G, 2000). At radiopharmacy II, not all 
radiopharmaceutical vials are subjected to sterility testing, thus we do not know if the contaminated 
eluate did lead to contamination of kits prepared on the same day. In the more optimal situation of 





One of the aims of the MFT is to indicate if sterility problems are due to operator technique rather than 
to environmental factors. All four operators at radiopharmacy I involved in the preparation and 
dispensing of radiopharmaceuticals were new to the MFT technique and repeated the validation exercise 
more than twice. Thereafter they seemed to become familiar with the process by successfully completing 
the validation test. Three workers completed all the tests without contaminating vials during the filling 
process. A newly appointed staff member contaminated 1 % of the MFT vials and also had the highest 
rate of contaminated fingertips.  
Observation of the newly recruited operator at radiopharmacy I during the test revealed inadvertent 
touching of vial septa and omitting disinfection of the vial prior to puncture. This case illustrates the 
importance of strict adherence to decontamination procedures. Fingertip failure at radiopharmacy I is 
most likely due to incorrect cleaning of the work station, including the use of tap water before 
disinfection with ethanol. The cleaning procedure has been altered, and suitable disinfecting procedures 
have been implemented. 
The MFT operators’ failure rate were 35% at Radiopharmacy I and 6% at radiopharmacy III, and the 
contamination rates during vial filling process were 0.3% and 0% respectively. The number of plates 
contaminated from fingertip operation was higher than the number of vials contaminated from MFT in 
both centres. There seems to be no association between the operator’s experience and the fingertip 
results. Sigward and co-workers found no association between staff members’ years of experience and 
media fill results (Sigward et al. 2012). The fact that even experienced staff sometimes fail media fill or 
fingertip tests, supports the need for improving guidelines for good pharmacy practice.  
The contaminating microorganism found in the MFT vial at radiopharmacy I was Staphylococcus 
epidermidis, which was also identified in the eluate vials during the sterility testing in this study. This 
matches several reports of contamination of sterile products with microorganisms associated with 
human skin. The contamination of sterility test samples and media fill vials in radiopharmacy I took 
place during a period in which students observed work in the radiopharmacy, i.e. while there was 





For better control of microbial safety of radiopharmaceuticals, the QA programme in both these African 
radiopharmacies includes environmental monitoring. Results of passive air sampling in radiopharmacies 
I and II during similar time periods as the sterility tests reported here, are the subject of another 
publication (see chapter 5). However, no air quality results were available for the dates of the failed 
sterility test samples. At both radiopharmacies only a fraction of radiopharmaceutical products are 
submitted for sterility testing, and air quality monitoring was not done every day. Thus it is not possible 
to directly link the sterility failure to specific air quality results. The frequency of both air quality 
monitoring and sampling for sterility testing should be increased if the relationship between air quality 
and sterility failures were to be investigated, especially in radiopharmacies operating without clean room 
facilities. 
The findings of the current work revealed similar contamination levels to those described in literature 
(Weatherman 2013). Technetium-99m radiopharmaceuticals are prepared as multi-dose vials, but the 
contents are used within 6 to 8 hours. The risk of micro-organisms multiplying in radiopharmaceutical 
vials is relatively low compared to other pharmaceuticals with longer shelf-lives. The possibility of a 
patient developing an infection after administration of a contaminated radiopharmaceutical is small but 
definitely present. Both radiopharmacies should therefore strive to improve their quality management 
in order to reach a 0% microbial contamination rate.  
 
Conclusion 
This paper describes successful evaluation of sterility testing of radiopharmaceutical compounds, 
prepared in two African radiopharmacies. An important finding of the study was that, in general, there 
were only a very small number of positive sterility tests. The percentage of microbially contaminated 
eluate in radiopharmacy I was higher than that for radiopharmacy II. Media fill tests helped 
radiopharmacy I to identify serious deviations from aseptic technique which were corrected by retraining 





that were introduced in radiopharmacy I in response to a self-audit. Implementation of similar quality 
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Discussion and Conclusion 
 
Recommendations and rules from national and international regulatory bodies for SPECT 
radiopharmaceuticals are sometimes not fully adhered to due to limited funding allocated to healthcare 
in developing countries. To address regulatory requirements, an optimized quality assurance programme 
can assist in ensuring the efficacy and safety of pharmaceutical products. 
The aim of this study was to investigate the conditions to ensure safe and efficacy of products. Different 
aspects that influence the quality of radiopharmaceuticals are addressed in this dissertation in five 
chapters. Two radiopharmacies in teaching hospitals in Africa (Yaoundé General Hospital and 
Tygerberg Hospital) are used as examples, with a GMP-compliant radiopharmacy in the Netherlands 
serving as a model of a facility that meets requirements of international guidelines. The identification of 
important factors was done by self-audits in the radiopharmacies. The first topic addressed was the 
identified need for validation of methods at YGH, resulting in validation of a radioactivity quantification 
method for RCP determination. Further chapters address the microbial safety of radiopharmaceuticals 
at YGH and TBH, including air quality monitoring, sterility testing of products at YGH and TBH, and 
the evaluation of aseptic work skills of staff at YGH. 
 
The IAEA’s QUANUM tool was adapted by incorporating elements of an earlier IAEA questionnaire 
for radiopharmacy to specifically address GRP. This modified version of the audit instrument was very 
useful to establish the status of radiopharmacy practice in the radiopharmacies included in this 
dissertation. The findings of the self-audits are reflected by the results of microbiological studies 
described in later chapters of the dissertation. 
Based on the outcome of the initial quality audit at YGH, relatively simple, affordable corrective actions 





introduction of annual performance reviews, installation of a transfer hatch, rearrangement of room lay-
out, and improved record keeping. The re-evaluation of the radiopharmacy at YGH demonstrated clear 
improvement in the quality of practice. Additional, more complex or higher cost improvements were 
recommended to hospital management.  
Radiochemical purity (RCP) is a key factor determining the biodistribution and therefore efficacy of 
radiopharmaceuticals. To evaluate the reliability of the method for radiochemical purity determination 
at YGH, an experimental validation of the method for quantification of the distribution of radioactivity 
on radiochromatograms was conducted using the method of the GMP-accredited UMCG radiopharmacy 
as comparator. The value of this study was two-fold: Firstly, it demonstrated validation of a method in 
radiopharmacy addressing all relevant parameters internationally recommended for validation of 
analytical methods. Secondly, the use of a simple alternative device for counting the radioactivity on 
thin layer strips was validated and can be implemented in daily work at YGH. This method, employing 
a small contamination monitor, may also be useful for other radiopharmacies. 
The use of settle plates to monitor air quality in radiopharmacies can be implemented without the need 
for specialised air samplers or particle counters. The method demonstrated that viable organisms were 
often present in the areas where radiopharmaceuticals are prepared in the two African radiopharmacies 
studied in this work. In addition, YGH introduced several corrective actions, aiming improvement of 
the air quality, and their beneficial effect was clearly demonstrated. Nevertheless, the air quality in the 
closed cabinet at YGH was still far from the recommended class A clean air level. Despite the lack of a 
clean room, the results at TBH demonstrate the value of correct use of a well-maintained type II 
biosafety laminar air flow cabinet to provide the best possible environment for preparation of Tc-99m 
radiopharmaceuticals.  
Having evaluated the air quality in the radiopharmacies, the next question addressed the impact of air 
quality and staff competency on the sterility of radiopharmaceuticals. Although the microbiological 
contamination rates of radiopharmaceuticals in both African radiopharmacies is low, both should strive 
to improve their performance to prevent possible serious consequences for patients. Media fill testing is 






Summary of limitations 
A weakness of the current study is the fact that the work is based only in two African radiopharmacy 
units, which limits the extent to which the conclusions and recommendations can be generalised. 
Unfortunately, including radiopharmacies from more African countries in the study was not feasible. 
Furthermore, the audits included in the work were self-assessments performed by staff members from 
the respective radiopharmacies who may have interpreted the audit questions differently. For complete 
adherence to international standards, external audits are recommended. For a true comparison of 
different practices, a single audit team should evaluate facilities. However, the aim here was not to 
perform a quantitative comparison of the three radiopharmacies, but to demonstrate the level of 
adherence to GRP. 
Limitations of the validation study are described in chapter 3.  An important aspect that should be taken 
into account in the validation of any method to measure radioactive samples, is to include the entire 
range of possible activities to be measured.  
Due to limited availability of radiopharmaceuticals and the fact that our sterility samples were taken 
from the volume remaining in radiopharmaceutical vials after patient doses were dispensed, our sterility 
sample numbers were relatively small. Larger sample sizes for sterility tests and media fill tests (e.g. 
collected over a longer time period) would allow a more reliable statistical comparison of the different 
radiopharmacies, and possibly permit better analysis of relationships between the different aspects of 
microbial monitoring addressed in this work.   
 
Future directions 
Further work can support the findings of this study. Surface sampling at critical locations in the 
radiopharmacies would help to provide more complete monitoring data for microbial safety of 





pharmacopoeial methods (using different incubation temperatures and longer incubation) would be 
feasible at least in LAF cabinets which demonstrated low settle plate contamination rates in the current 
study. Collecting more data on both sterility of radiopharmaceuticals and air quality would allow better 
statistical analysis. Lastly, based on the useful outcomes from the work described in this dissertation, 
another attempt can be made to obtain permission to expand the study by collecting data at more African 
radiopharmacies, to reflect a broader range of circumstances. 
 
Recommendations for future improvement and development at YGH: 
• Training of a medical physicist for the nuclear medicine department, who would be, amongst others, 
responsible for regular QC of equipment; 
• Training of an engineer to service and as far as possible repair radiopharmacy and nuclear medicine 
equipment; 
• Designing the new radiopharmacy to have all rooms (e.g. change room, radiopharmaceutical 
preparation room, QC room, etc.), adjacent to each other, with a layout that allows unidirectional 
movement of staff and products;  
• Emphasize again the earlier recommendations regarding a clean room facility for the 
radiopharmacy.  
 
Recommendations for future improvement and development of TBH radiopharmacy: 
• Implement broth fill and fingertip tests to evaluate competency of staff preparing 
radiopharmaceuticals in laminar flow cabinets; 







Тhe results obtained in this doctorate will contribute significantly to enhancing the quality of work 
and implementation of quality assurance standards in radiopharmacies in low-income countries: 
• The adapted QUANUM tool described in the current work should be useful for audits by African 
radiopharmacies. 
• Other radiopharmacies working under comparable conditions can use the methods described in this 
study as an example of implementing good practice for radiopharmacies. 
• Investment in establishing and maintaining well-designed clean room facilities and suitable 
equipment for quality control monitoring remains the best option for ensuring safety and efficacy 
of radiopharmaceuticals. Where this is financially not feasible, a good quality management system, 
a correctly used and well-maintained good LAF, appropriate staff training and evaluation of their 
competence as well as strict adherence to aseptic technique can to a large extent overcome the 
disadvantages of a sub-optimal facility.  
 
Conclusion 
Requirements for radiopharmacy design and procedures described in international guidelines cannot all 
be met by radiopharmacies in many African countries, including Cameroon and South Africa. Factors 
affecting the safety and efficacy of radiopharmaceuticals at TBH and YGH are described in this work. 
The sub-optimal facility and lack of equipment maintenance negatively impact the air quality at YGH, 
but simple structural and procedural improvements lowered the level of microbes detected by passive 
air sampling. The better facility and well-maintained equipment at TBH demonstrated better air quality 
in the radiopharmacy, despite the lack of a classified pharmaceutical clean room. 
The results obtained in this study indicate that implementation of a good quality management plan can 
make a major contribution to safety and efficacy of radiopharmaceuticals even if the facility and 
equipment cannot meet internationally recommended standards. 
The scientific value of the study lies in its originality as no published work is available until now 





study provides useful information to hospital radiopharmacy facilities in many African countries and 
















Addendum to Chapters 1 and 2 
Table A.1  Status of SPECT radiopharmacy at the three hospitals  
Components Status YGH Status TBH Status UMCG 
Staff and training Responsible person: MSc 
Radiopharmacy 
1 Nuclear Medicine technician with 
six months training in a well-
equipped unit  
1 Scientist with a Bachelor’s degree 
in Biology with 4 months training in 
a well-equipped unit  
1 Scientist with a Bachelor’s degree 
in Biology and European course in 
radiopharmacy level 1   
Responsible pharmacist: PhD, registered 
specialist in Radiopharmacy 
7 Nuclear Medicine radiographers 
(technologists) take turns to work 1 week 
in the radiopharmacy (National diploma or 
degree course includes Radiopharmacy 
theory and practice 
3 Qualified Persons (Pharmacist/ PhD, 2 
Clinical Pharmacists),  
4 Radiochemists (PhD, 2 Clinical 
Radiochemists),  
2 GMP-officers (1 BSc),  
15 technicians for Radiopharmacy 






1 Chief nurse with 3 months training 
in a well-established unit in Europe 
Facility (rooms) 2 rooms, not cleanroom status Separate rooms for receipt and unpacking, 
radiopharmaceutical preparation, QC, cell 
labelling 
Not cleanroom status 
One room for receipt, quarantine storage 
with fridge and freezer as well as 
unpacking.  
2 Cleanroom facilities: one for Shortliving 
radiopharmaceuticals (PET) and one for 
longer living radiopharmaceuticals 
(SPECT, Therapy and 89Zr-PET) 
Separate QC room. 
Equipment 1 glove box (not clean air) 
1 fume hood 
1 laminar air flow cabinet  
1 shielded dispensing area   
1 dose calibrator  
Shielded LAF cabinet for preparation and 
dispensing of radiopharmaceuticals, 
includes generator safe with lift mechanism 
Biohazard class II LAF for cell labelling 
2 dose calibrators 
Chromatography scanner 
SPECT facility: 3 LAF-hoods and one 
Hotcell Grade A/B for aseptic filling of 
89Zr-antibodies.  
QC facility UPLC, HPLC, endotoxin 
testing, sterility testing, chromatogram 





3 contamination monitors  Well counter 
2 Centrifuges 
Several contamination monitors 
etc. 





DTPA (diethylene triamine penta 
acetic acid), HMDP (hydroxy 
methylene diphosphonate), 
nanocolloid (colloidal rhenium 
sulphide), DMSA 
(dimercaptosuccinic acid) 
99mTc: MIBI, DTPA, MAG3, DMSA, 
MDP, nanocolloid, tin colloid, HMPAO, 
MAA, Technegas, Pyrophosphate, etc. 
RBC and Leucocytes 
123I: NaI, MIBG 
111In: platelets 
99mTc: Pertechnetate, MAG3, tetrofosmin, 
DTPA, DMSA, HDP, nanocolloid, tin 
colloid, HMPAO, MAA, mebrofenin, 
HMPAO, HSA, RBC, 99mTc-labelled 
Leucocytes  
Krypton generator 
123I: NaI, MIBG, SAP (Serum Amyloid 
Protein). 








Details of self-audits at the three radiopharmacies discussed in this study 
The questions in the tables below were published by the IAEA in the Operational Guidance on 
Hospital Radiopharmacy: A Safe and Effective Approach in 2008. This publication also provides 
background information on the requirements for hospital radiopharmacies working at different 
operational levels. The questions address those requirements. 
 
In the following tables the answers Yes or No are presented in the format Y/Y, with the first answer 
indicating the initial audit status, and the second answer relating to the follow-up audit.  
Questions numbers starting with “1.” are relevant for operational level 1, and “2.” for operational level 
2.  Class A indicates aspects that are required and that should be addressed urgently, class B standards 
should be reached although they are not compulsory. 
The level of conformance (LoC) was graded as follows:  
0  the component was absent in the unit 
1  the component was planned 
2  the component was partially implemented 
3  the component was largely implemented 
4  the component was fully implemented 
 
Items scoring 0, 1, or 2 are considered non-compliant.  
Items scoring 3 and 4 are considered compliant. 





Table A.2  Staffing scoring 









Y or N TBH Score Y or N UMCG 
score 
1.1 
Is there a professional responsible for 
the radiopharmacy? Provide details. 
A Y/Y 4 4 Y 4 Y 4 
1.2 
Is the radiopharmacy unit operated 
under the direction of a person with 
appropriate training as defined by local 
or national regulations? 
A Y/Y 4 4 Y 4 Y 4 
1.3 
Are there written staff training manuals 
for all grades of staff? 
B N/Y 0 3 N 0 Y 4 
2.1a 
Calibration of equipment- please 
provide details and training records 
A N/N 0 0 Y 3 Y 4 
2.1b 
Working practices in the radiopharmacy 
- please provide details and training 
records 







Preparation of individual doses - please 
provide details and training records 
A Y/Y 4 4 Y 3 Y 4 
2.1d 
Quality control and analytical 
techniques - please provide details and 
training records 
A N/Y 1 3 Y 3 Y 4 
2.1e 
Dose release - please provide details 
and training details 
A Y/Y 4 4 N 2 Y 4 
2.1f 
Record keeping - please provide details 
and training records 
A Y/Y 3 3 Y 3 Y 3 
2.1g 
Cleaning - please provide details and 
training records 
A Y/Y 3 3 N 2 Y 4 
2.2 
Is there a system for formal approvals 
of all documentations including 
radiopharmaceutical (RP) preparation, 
QC and formal release to patient? 
B N/Y 3 3 Y 4 Y 4 
2.3 
What training is provided to staff 
performing final checks on all products 
prepared before release for patient use? 






Are there training records for all staff 
performing cell labelling, e.g. RBC, 
WBC? 
B n/a   N 1 Y 4 
2.5 
Is there an annual performance review 
to check the competencies of 
radiopharmacy staff? 
B N/Y 0 3 N 1 Y 4 
Total 29 40  36  55 
Maximum possible score 52 52  56  56 
Score (%) 56% 77%  64%  93% 
Conforming 8 12  9  14 
Non-conforming 5 1  5  0 







Table A.3  Facility scoring 









Y or N TBH Score Y or N UMCG 
score 
1.4 
Does the unit have appropriately 
finished rooms (including adequate 
lighting, appropriate finishes to walls, 
floors, ceilings and ventilation) and a 
shielded dispensing station? 
A N/N 0 0 Y 3 Y 4 
1.5 
Is there a shielded dispensing station 
available? 
A Y/Y 3 3 Y 4 Y 4 
1.6a 
For operational level 1b is there a 
shielded dispensing station and/or a 
fume hood available? [Is there a fume 
cupboard with suitable filters for 
volatile radioactive materials such as 
131I solutions?] 







[If only radioiodine capsules are 
handled is the package opened in a 
well-ventilated area?] 
A N/Y 0 3 Y 4 Y 4 
1.7 
Is there a validated (annual check on 
air-flow, safety and challenge testing) 
fume hood with suitable filters for 
handling radioiodine solutions? 
A N/N 0 0 Y 3 Y 4 
1.8 
Are there records and logs kept for all 
equipment irrespective of whether 
maintenance and calibration is 
performed ‘in-house’ or by external 
contractors? 
B Y/Y 3 3 Y 3 Y 4 
2.6 
For operational level 2: Are there 
regular checks on validated Class II 
type B microbiological safety cabinets 
located in a dedicated room? 
A N/Y 0 3 Y 4 Y 4 
2.7 
Are manometer readings of pressure 
differentials across HEPA filters 
recorded daily? 






Are there periodic records of air 
velocity determination for LAF cabinets 
or isolators? 
B N/Y 0 3 Y 3 Y 4 
2.9 
Is challenge testing of the HEPA filters 
in LAFs and isolators carried out 
annually? 
B N/N 0 0 Y 4 Y 4 
2.10 
For negative pressure isolators: Before 
preparation takes place, are gloves or 
gauntlets visually inspected and 
integrity tests carried out and recorded? 
B n/a   n/a  Y 4 
2.11 
Is there a system and record of planned 
preventative maintenance for all 
equipment in the radiopharmacy 
including the refrigerator? 
B N/N 0 0 Y 3 Y 2 
2.12 
When clean rooms are used, are the 
over-pressures gauges monitored and 
recorded daily? 






Total 9 24  37  50 
Maximum possible score 48 48  48  52 
Score (%) 18.8% 50.0%  77.0%  96.1% 
Conforming 3 8  10  12 
Non-conforming 9 4  2  1 







Table A.4  Purchase of materials scoring 









Y or N TBH Score Y or N UMCG 
score 
1.9 
Are there suitable protocols and trained 
staff for the purchase of approved or 
Marketing Authorized 
radiopharmaceuticals? 
A N/Y 0 3 Y 3 Y 4 
1.10 
Are all goods received checked and 
recorded against the order for 
correctness of delivery? 
B N/Y 0 3 Y 3 Y 4 
1.11 
Are records kept for batch numbers and 
quantities received? 
B N/Y 0 4 Y 4 Y 4 
1.12 
Are visual inspections and label checks 
carried out prior to acceptance? 
B Y/Y 3 4 Y 3 Y 4 
2.13 
Do all products, kits and generators 
have product approval, marketing 
authorisation, or bear a product licence 
number? 






How many unlicensed or unapproved 
products are used each year and is there 
a record of them? 
A n/a   Y 4 Y 4 
2.15 
For all unlicensed kits, 
radiopharmaceuticals or radio-
chemicals are the prescribers or 
responsible medical doctors made 
aware of his/her responsibilities? 
A n/a   Y 4 Y 4 
2.16 
Do the suppliers or reagents and 
unapproved products provide a 
"Certificate of Analysis"? 
B Y/Y 4 4 Y 3 Y 4 
Total 11 22  28  32 
Maximum possible score 24 24  32  32 
Score (%) 45.8% 98.4%  87.5%  100.0% 
Conforming 3 6  8  8 
Non-conforming 3 0  0  0 






Table A.5  Dispensing protocols scoring 









Y or N TBH Score Y or N UMCG 
score 
1.13 
Are there specific written 
radiopharmacy procedures for 
dispensing operations undertaken in the 
radiopharmacy? 
B N/Y 2 4 Y 4 Y 4 
1.14 
Under operational level 1a: Are there 
written procedures for the aseptic 
dispensing and labelling of unit doses of 
ready-to-use radiopharmaceuticals? 
B n/a   Y 4 Y 4 
1.15 
Is there a system for labels which 
assesses quality, number produced and 
number applied to dispensed doses? 
A Y/Y 3 4 n/a  Y 4 
1.16 
For operational level 1b: Do the written 
procedures contain clear safety and 
monitoring instruction for dispensing 
radioiodine solutions or capsules? 






Under operational level 1b are there 
written procedures for calibration assay, 
preparation and dispensing of individual 
patient radionuclide therapy? 
A N/Y 0 3 Y 4 Y 3 
1.18 
Can the audit and documentation for 
each RP batch be traced from the 
prescription to the actual administration 
of individual patient doses? 
A Y/Y 3 4 Y 4 Y 4 
Total 8 19  18  22 
Maximum possible score 20 20  20  24 
Score (%) 40.0% 95.0%  90.0%  91.6% 
Conforming 2 5  4  6 
Non-conforming 3 0  1  0 







Table A.6  Preparation protocols scoring 









Y or N TBH Score Y or N UMCG 
score 
2.17 
Are there written and approved 
procedures for the use of generators and 
reconstitution of each 
radiopharmaceutical kit used? 
A Y/Y 4 4 Y 4 Y 4 
2.18 
Are SOPs independently reviewed and 
approved at specified intervals? 
B N/Y 1 3 Y 3 Y 4 
2.19 
Is the preparation of 99mTc 
radiopharmaceuticals from kits and 
generators carried out in a LAF cabinet? 
A Y/Y 4 4 Y 4 Y 4 
2.20 
Are there set criteria before release for 
preparation for patients use? Is this 
undertaken by the same operator or a 
different individual? 
B N/Y 1 3 Y 3 Y 4 
2.21 
Can each individual patient dose be 
traced to a specific generator and kit 
batch number? 






Under operational level 2b: Do the 
written procedures for any autologous 
preparation, e.g. red and white blood 
cells, include a clear instructions on 
safety, cleaning and decontamination? 
A n/a   Y 4 Y 4 
2.23 
Are there written procedures for the 
preparation and dispensing of approved 
kit formulations of radio-labelled 
biological e.g. monoclonal antibodies, 
peptides? 
A n/a   n/a  Y 4 
Total 11 17  22  28 
Maximum possible score 20 20  24  28 
Score (%) 50.0% 85.0%  92.0%  100.0% 
Conforming 2 5  6  7 
Non-conforming 3 0  0  0 






Table A.7  QA/QC scoring 









Y or N TBH Score Y or N UMCG 
score 
1.19 
Are daily QC checks performed on 
radionuclide calibrators? 
A Y/Y 4 4 Y 4 Y 4 
1.20 
What quality checks are undertaken on 
a supplier before purchase? 
B Y/Y 4 4 Y 3 Y 4 
1.21 
Are periodic quality checks on 
radiopharmaceuticals (RP) performed? 
B N/Y 1 4 Y 4 Y 4 
1.22 
Is there a written procedure for dealing 
with product/s failing to meet the 
required standard? 
B N/Y 0 4 N 0 Y 4 
1.23 
Is there a record of complaint/s and any 
associated follow-up and investigation? 
B N/Y 0 4 Y 4 Y 4 
1.24 
Are there written procedures and 
records for regular contamination 
surveys of the radiopharmacy unit? 






For operational level 2 are there 
records for the following: 
B        
2.24a 
Purchase of radioactive products and 
ingredients 
B Y/Y 4 4 Y 4 Y 4 
2.24b 
Generator elution, yield, [99Mo] 
molybdenum breakthrough and 
aluminium ion breakthrough 
B Y/Y 4 4 Y 4 Y 3 
2.24c Product preparation, QC and release B N/Y 0 4 Y 3 Y 4 
2.24d 
Environmental and microbiological 
monitoring 
B N/Y 0 3 Y 3 Y 4 
2.24e 
Aseptic process, aseptic operator 
validation and trend analysis 
B N/Y 0 4 N 0 Y 4 
2.24f Laboratory cleaning and maintenance B N/Y 0 4 N 0 Y 3 
2.24g 
Equipment and plant calibration and 
maintenance 
B N/N 0 0 Y 3 Y 3 
2.24h 
Radioactive contamination monitoring 
and radioactive waste disposal 






Product defects and SOPs non- 
conformance, i.e. when a procedure is 
performed in a manner other than that 
described in the relevant SOP 
B N/Y 0 3 Y 4 Y 4 
2.24j Independent inspection and audit B N/Y 0 3 N 1 Y 4 
2.25 
In line with the IAEA “Operational 
guidance on Hospital Radiopharmacy” 
document, are there records of routine 
microbiological monitoring of the 
preparation area in the radiopharmacy? 
A N/Y 0 3 Y 3 Y 4 
2.26 
Are there calibration and linearity 
checks of the dose calibrator response 
over the complete range of activities 
measured at least annually? 
A Y/Y 3 4 Y 4 Y 4 
2.27 
Is there set programme for checking the 
quality of radiopharmaceuticals (RP)? 
B N/Y 0 4 Y 4 Y 4 
2.28 
Considering patient safety, are certain 
simple checks performed on prepared 
radiopharmaceutical, e.g. mini-
chromatography? 






For operational level 2 is a [99Mo] 
Molybdenum breakthrough 
measurement performed on the first 
eluate from each [99mTc] Technetium 
generator and repeated when the 
generator is moved? 
A Y/Y 4 4 Y 4 Y 4 
2.30 
Is aluminium ion breakthrough checked 
on the first eluate from a [99mTc] 
Technetium generator? 
A N/N 0 0 Y 4 N 0 
2.31 
Are changes in the source of any kits, 
diluents or vehicle used, needles, 
syringes, swabs and sterile containers 
used within radiopharmacy recorded? 
B N/Y 0 3 N 1 Y 4 
2.32 
On first use of a new batch or first new 
delivery of RP kits is radiochemical 
purity performed? 
B N/Y 0 4 Y 4 Y 4 
2.33 Laboratory cleaning and maintenance A n/a   Y 4 Y 3 
2.34 
Is there regular pH testing of RP carried 
out? 






Prior to release for patients is each 
individual radioactivity dose checked? 
A Y/Y 3 4 Y 4 Y 4 
2.36 
Is there a record of the formal 
approval/release by an authorized 
person before a product is administered 
to a patient? 
A Y/Y 3 4 N 0 Y 4 
2.37 
Are there written procedures for the 
recall of defective products? 
A N/Y 0 4 n/a  Y 4 
2.38 
Is there a record of complaints and any 
associated follow-up and investigation? 
B Y/Y 3 4 Y 4 Y 4 
2.39 
Is there a system of recorded self-
inspection and reports evaluation? 
B N/Y 0 3 N 0 Y 4 
2.40 
Is there a system for external audit or 
peer review process? 
B N/N 0 0 N 1 Y 4 
Total 36 104  87  117 
Maximum possible score 124 124  124  128 





Conforming 10 28  23  31 
Non-conforming 21 3  8  1 







Table A.8  Waste scoring 









Y or N TBH Score Y or N UMCG 
score 
1.25  A Y/Y 4 4 Y 4 Y 4 
1.26  A N/Y 0 4 N 0 Y 4 
1.27  A Y/Y 4 4 Y 4 Y 4 
Total 8 12  8  12 
Maximum possible score 12 12  12  12 
Score (%) 66.7% 100.0%  67.0%  100.0% 
Conforming 2 32  2  3 
Non-conforming 1 0  1  0 

























Figure A.1 Summary of radiopharmacies’ level of compliance. For radiopharmacy at YGH, the compliance is shown for the initial audit  
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Addendum to Chapter 5 
Table A.9  Fisher's exact test of data from plate exposure  
at Radiopharmacy I versus Radiopharmacy II 
Area Rest Work 
Where RP are prepared (Class A) P < 0.01* P < 0.001* 
Other Class A LAF P > 0.05 P > 0.05 
Class C P < 0.05* P > 0.05 
 * Difference between Radiopharmacy I and Radiopharmacy II is statistically significant  
 
 
Table A.10  Fisher's exact test of data from plate exposure  
rest versus work at Radiopharmacies I and II 
Area Radiopharmacy I  Radiopharmacy II 
Where RP are prepared (Class A) P > 0.05 P > 0.05 
Other Class A LAF P > 0.05 P > 0.05 
Class C P > 0.05 P > 0.05 
Class D P > 0.05 n/a 
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